

Author index*

A

- Abe M (see Tomiyama et al). 2001;141:422-7
 Abizaid A (see Mehran et al). 2001;141:610-14
 Abramowitz BM (see Labinaz et al). 2001;141:469-77
 Abrams J (see O'Connell et al). 2001;141:251-8
 Adams KF Jr. Which β -blocker for heart failure? 2001;141:884-8 (Editorial)
 Adams KF Jr (see Shah et al). 2001;141:908-14
 Ahmed N (see Tousoulis et al). 2001;141:277-80
 Aikawa Y, Rohde L, Plehn J, Greaves SC, Menapace F, Arnold JMO, Rouleau J-L, Pfeffer MA, Lee RT, Solomon SD. Regional wall stress predicts ventricular remodeling after anteroapical myocardial infarction in the Healing and Early Afterload Reducing Trial (HEART): An echocardiography-based structural analysis. 2001;141:234-42
 Albert MA, Staggars J, Chew P, Ridker PM, PRINCE Investigators. The Pravastatin Inflammation CRP Evaluation (PRINCE): Rationale and design. 2001;141:893-8 (Trial design)
 Alboni P (see Mele et al). 2001;141:653-60
 Alexopoulos D (see Hahalis et al). 2001;141:428-34
 Almer Z (see Sharabi et al). 2001;141:1014-7
 Alpert JS (see Mahaffey and Alpert). 2001;141:321-4 (Editorial)
 Amoroso G, Van Boven AJ, Crijns HJGM. Drug therapy or coronary angioplasty for the treatment of coronary artery disease: New insights. 2001;141:522-5
 Amos DJ, French JK, Andrews J, Ashton NG, Williams BF, Whitlock RML, Manda SOM, White HD. Corrected TIMI frame counts correlate with stenosis severity and infarct zone wall motion after thrombolytic therapy. 2001;141:586-91
 André F (see Cottin et al). 2001;141:999-1006
 Andrews J (see Amos et al). 2001;141:586-91
 Angeja B (see Barron et al). 2001;141:933-9
 Angeja BG, Gibson CM. Preserved coronary flow reserve in viable myocardium: Further evidence for the microvascular hypothesis. 2001;141:329-30 (Editorial)
 Angus C (see McPherson et al). 2001;141:949-56
 Anker SD (see Doehner et al). 2001;141:792-9
 Antman EM (see de Lemos et al). 2001;141:592-8
 Antman EM (see Giugliano et al). 2001;141:742-50
 Antman EM (see Santopinto et al). 2001;141:566-72
 Antonopoulos GV (see Packer et al). 2001;141:899-907
 Aquilina JW (see Kereiakes et al). 2001;141:348-52
 Arad M (see Shotan et al). 2001;141:478-84
 Argatroban in Acute Myocardial Infarction-2 (ARGAMI-2) Study Group (see Rott et al). 2001;141:267-76
 Angel MI (see Laguens et al). 2001;141:780-3
 Arnold JMO (see Aikawa et al). 2001;141:234-42
 Asbeck F (see Frilling et al). 2001;141:200-5
 Ashton NG (see Amos et al). 2001;141:586-91
 Asimakopoulou G (see Tousoulis et al). 2001;141:277-80
 Aukrust P (see Gullestad et al). 2001;141:418-21
 Ausiello JC (see Wang et al). 2001;141:957-63
 Aveta P (see Modena et al). 2001;141:41-6
 AVID Investigators (see Exner et al). 2001;141:99-104
 AVID Investigators (see Kron et al). 2001;141:92-8
 Awaya T (see Ohba et al). 2001;141:751-8
 Ayabe S (see Kozuma et al). 2001;141:124-30
 Azar RR, Waters DD. PRINCE's prospects: Statins, inflammation, and coronary risk. 2001;141:881-3 (Editorial)

B

- Babić R (see Maras et al). 2001;141:e8
 Bachmann GA (see Raggi et al). 2001;141:722-6 (Trial design)
 Badano L (see Giannuzzi et al). 2001;141:131-8
 Bahit MC (see O'Shea et al). 2001;141:306-18 (Meetings)
 Bailey KR (see Wilson et al). 2001;141:704-10 (Prog. cardiol.)
 Baim DS (see Silva et al). 2001;141:353-9
 Baker RL (see Sticherling et al). 2001;141:813-16
 Bar-Or D, Winkler JV, VanBenthuyzen K, Harris L, Lau E, Hetzel FW. Reduced albumin-cobalt binding with transient myocardial ischemia after elective percutaneous transluminal coronary angioplasty: A preliminary comparison to creatine kinase-MB, myoglobin, and troponin I. 2001;141:985-91
 Baran KW (see Webb et al). 2001;141:964-70
 Barbash GI (see Birnbaum et al). 2001;141:915-24
 Barillot I (see Cottin et al). 2001;141:999-1006
 Barko W (see Taylor et al). 2001;141:463-8
 Barron HV, Every NR, Parsons LS, Angeja B, Goldberg RJ, Gore JM, Chou TM, National Registry of Myocardial Infarction 2 Investigators. The use of intra-aortic balloon counterpulsation in patients with cardiogenic shock complicating acute myocardial infarction: Data from the National Registry of Myocardial Infarction 2. 2001;141:933-9
 Baruch L, Patacsil P, Hameed A, Pina I, Loh E. Pharmacodynamic effects of milrinone with and without a bolus loading infusion. 2001;141:e6
 Batchelor W (see Jong et al). 2001;141:218-25
 Baumgärtel B (see Frilling et al). 2001;141:200-5
 Bavelaar-Croon CDL, Pauwels EKJ, van der Wall EE. Gated single-photon emission computed tomographic myocardial imaging: A new tool in clinical cardiology. 2001;141:583-90
 Becker RC, Eisenberg P, Turpie AGG. Pathobiologic features and prevention of thrombotic complications associated with prosthetic heart valves: Fundamental principles and the contribution of platelets and thrombin. 2001;141:1025-37 (Meetings)
 Behar S (see Fisman et al). 2001;141:485-90
 Behar S (see Rott et al). 2001;141:267-76
 Behar S (see Shotan et al). 2001;141:478-84
 Bell L (see Clark et al). 2001;141:684-90
 Bell MR (see Wilson et al). 2001;141:704-10 (Prog. cardiol.)
 Bella JN (see Palmieri et al). 2001;141:784-91
 Beller GA (see Ragosta et al). 2001;141:456-62
 Belli G (see Ziada et al). 2001;141:823-31
 Bellocchi F (see Lanza et al). 2001;141:808-12
 Ben-Cnaan R (see Sharabi et al). 2001;141:1014-7
 Berger PB (see Rathore et al). 2001;141:47-54
 Berger PB (see Wilson et al). 2001;141:704-10 (Prog. cardiol.)
 Berlioli S (see Wang-Clow et al). 2001;141:33-40
 Berkowitz SD. Antithrombotic therapy after prosthetic cardiac valve implantation: Improving postoperative, long-term patient management—Introduction. 2001;141:847-8 (Meetings)
 Berkowitz SD (see Madan et al). 2001;141:226-33
 Berlin JA (see Packer et al). 2001;141:899-907
 Berlin JA (see Shammash et al). 2001;141:148-53
 Beyne P (see Logeart et al). 2001;141:247-53
 Bhatt DL (see Cho et al). 2001;141:599-602
 Birnbaum Y, Criger DA, Wagner GS, Strasberg B, Mager A, Gates K, Granger CB, Ross AM, Barbash GI. Prediction of the extent and severity of left ventricular dysfunction in anterior acute myocardial infarction by the admission electrocardiogram. 2001;141:915-24
 Birnbaum Y (see Sgarbossa et al). 2001;141:507-17 (Curriculum cardiol.)
 Bjessmo S, Ivert T, Flink H, Hammar N. Early and late mortality after surgery for unstable angina in relation to Braunwald class. 2001;141:9-14 (Curriculum cardiol.)
 Bloch G (see Kennedy et al). 2001;141:e4 (Letter)
 Bluhmki E (see Wang-Clow et al). 2001;141:33-40

*January, pp. 1-172; February, pp. 173-318, S1-62; March, pp. 319-506; April, pp. 507-690; May, pp. 691-880; June, pp. 881-1074.

Author index*

A

- Abe M (see Tomiyama et al). 2001;141:422-7
 Abizaid A (see Mehran et al). 2001;141:610-14
 Abramowitz BM (see Labinaz et al). 2001;141:469-77
 Abrams J (see O'Connell et al). 2001;141:251-8
 Adams KF Jr. Which β -blocker for heart failure? 2001;141:884-8 (Editorial)
 Adams KF Jr (see Shah et al). 2001;141:908-14
 Ahmed N (see Tousoulis et al). 2001;141:277-80
 Aikawa Y, Rohde L, Plehn J, Greaves SC, Menapace F, Arnold JMO, Rouleau J-L, Pfeffer MA, Lee RT, Solomon SD. Regional wall stress predicts ventricular remodeling after anteroapical myocardial infarction in the Healing and Early Afterload Reducing Trial (HEART): An echocardiography-based structural analysis. 2001;141:234-42
 Albert MA, Staggars J, Chew P, Ridker PM, PRINCE Investigators. The Pravastatin Inflammation CRP Evaluation (PRINCE): Rationale and design. 2001;141:893-8 (Trial design)
 Alboni P (see Mele et al). 2001;141:653-60
 Alexopoulos D (see Hahalis et al). 2001;141:428-34
 Almer Z (see Sharabi et al). 2001;141:1014-7
 Alpert JS (see Mahaffey and Alpert). 2001;141:321-4 (Editorial)
 Amoroso G, Van Boven AJ, Crijns HJGM. Drug therapy or coronary angioplasty for the treatment of coronary artery disease: New insights. 2001;141:522-5
 Amos DJ, French JK, Andrews J, Ashton NG, Williams BF, Whitlock RML, Manda SOM, White HD. Corrected TIMI frame counts correlate with stenosis severity and infarct zone wall motion after thrombolytic therapy. 2001;141:586-91
 André F (see Cottin et al). 2001;141:999-1006
 Andrews J (see Amos et al). 2001;141:586-91
 Angeja B (see Barron et al). 2001;141:933-9
 Angeja BG, Gibson CM. Preserved coronary flow reserve in viable myocardium: Further evidence for the microvascular hypothesis. 2001;141:329-30 (Editorial)
 Angus C (see McPherson et al). 2001;141:949-56
 Anker SD (see Doehner et al). 2001;141:792-9
 Antman EM (see de Lemos et al). 2001;141:592-8
 Antman EM (see Giugliano et al). 2001;141:742-50
 Antman EM (see Santopinto et al). 2001;141:566-72
 Antonopoulos GV (see Packer et al). 2001;141:899-907
 Aquilina JW (see Kereiakes et al). 2001;141:348-52
 Arad M (see Shotan et al). 2001;141:478-84
 Argatroban in Acute Myocardial Infarction-2 (ARGAMI-2) Study Group (see Rott et al). 2001;141:267-76
 Angel MI (see Laguens et al). 2001;141:780-3
 Arnold JMO (see Aikawa et al). 2001;141:234-42
 Asbeck F (see Frilling et al). 2001;141:200-5
 Ashton NG (see Amos et al). 2001;141:586-91
 Asimakopoulou G (see Tousoulis et al). 2001;141:277-80
 Aukrust P (see Gullestad et al). 2001;141:418-21
 Ausiello JC (see Wang et al). 2001;141:957-63
 Aveta P (see Modena et al). 2001;141:41-6
 AVID Investigators (see Exner et al). 2001;141:99-104
 AVID Investigators (see Kron et al). 2001;141:92-8
 Awaya T (see Ohba et al). 2001;141:751-8
 Ayabe S (see Kozuma et al). 2001;141:124-30
 Azar RR, Waters DD. PRINCE's prospects: Statins, inflammation, and coronary risk. 2001;141:881-3 (Editorial)

B

- Babić R (see Maras et al). 2001;141:e8
 Bachmann GA (see Raggi et al). 2001;141:722-6 (Trial design)
 Badano L (see Giannuzzi et al). 2001;141:131-8
 Bahit MC (see O'Shea et al). 2001;141:306-18 (Meetings)
 Bailey KR (see Wilson et al). 2001;141:704-10 (Prog. cardiol.)
 Baim DS (see Silva et al). 2001;141:353-9
 Baker RL (see Sticherling et al). 2001;141:813-16
 Bar-Or D, Winkler JV, VanBenthuyzen K, Harris L, Lau E, Hetzel FW. Reduced albumin-cobalt binding with transient myocardial ischemia after elective percutaneous transluminal coronary angioplasty: A preliminary comparison to creatine kinase-MB, myoglobin, and troponin I. 2001;141:985-91
 Baran KW (see Webb et al). 2001;141:964-70
 Barbash GI (see Birnbaum et al). 2001;141:915-24
 Barillot I (see Cottin et al). 2001;141:999-1006
 Barko W (see Taylor et al). 2001;141:463-8
 Barron HV, Every NR, Parsons LS, Angeja B, Goldberg RJ, Gore JM, Chou TM, National Registry of Myocardial Infarction 2 Investigators. The use of intra-aortic balloon counterpulsation in patients with cardiogenic shock complicating acute myocardial infarction: Data from the National Registry of Myocardial Infarction 2. 2001;141:933-9
 Baruch L, Patacsil P, Hameed A, Pina I, Loh E. Pharmacodynamic effects of milrinone with and without a bolus loading infusion. 2001;141:e6
 Batchelor W (see Jong et al). 2001;141:218-25
 Baumgärtel B (see Frilling et al). 2001;141:200-5
 Bavelaar-Croon CDL, Pauwels EKJ, van der Wall EE. Gated single-photon emission computed tomographic myocardial imaging: A new tool in clinical cardiology. 2001;141:583-90
 Becker RC, Eisenberg P, Turpie AGG. Pathobiologic features and prevention of thrombotic complications associated with prosthetic heart valves: Fundamental principles and the contribution of platelets and thrombin. 2001;141:1025-37 (Meetings)
 Behar S (see Fisman et al). 2001;141:485-90
 Behar S (see Rott et al). 2001;141:267-76
 Behar S (see Shotan et al). 2001;141:478-84
 Bell L (see Clark et al). 2001;141:684-90
 Bell MR (see Wilson et al). 2001;141:704-10 (Prog. cardiol.)
 Bella JN (see Palmieri et al). 2001;141:784-91
 Beller GA (see Ragosta et al). 2001;141:456-62
 Belli G (see Ziada et al). 2001;141:823-31
 Bellocchi F (see Lanza et al). 2001;141:808-12
 Ben-Cnaan R (see Sharabi et al). 2001;141:1014-7
 Berger PB (see Rathore et al). 2001;141:47-54
 Berger PB (see Wilson et al). 2001;141:704-10 (Prog. cardiol.)
 Berlioli S (see Wang-Clow et al). 2001;141:33-40
 Berkowitz SD. Antithrombotic therapy after prosthetic cardiac valve implantation: Improving postoperative, long-term patient management—Introduction. 2001;141:847-8 (Meetings)
 Berkowitz SD (see Madan et al). 2001;141:226-33
 Berlin JA (see Packer et al). 2001;141:899-907
 Berlin JA (see Shammash et al). 2001;141:148-53
 Beyne P (see Logeart et al). 2001;141:247-53
 Bhatt DL (see Cho et al). 2001;141:599-602
 Birnbaum Y, Criger DA, Wagner GS, Strasberg B, Mager A, Gates K, Granger CB, Ross AM, Barbash GI. Prediction of the extent and severity of left ventricular dysfunction in anterior acute myocardial infarction by the admission electrocardiogram. 2001;141:915-24
 Birnbaum Y (see Sgarbossa et al). 2001;141:507-17 (Curriculum cardiol.)
 Bjessmo S, Ivert T, Flink H, Hammar N. Early and late mortality after surgery for unstable angina in relation to Braunwald class. 2001;141:9-14 (Curriculum cardiol.)
 Bloch G (see Kennedy et al). 2001;141:e4 (Letter)
 Bluhmki E (see Wang-Clow et al). 2001;141:33-40

*January, pp. 1-172; February, pp. 173-318, S1-62; March, pp. 319-506; April, pp. 507-690; May, pp. 691-880; June, pp. 881-1074.

- Bobrowsky K (see Khaleeli et al). 2001;141:637-44
Bošković SD (see Maras et al). 2001;141:e8
Bojić M (see Maras et al). 2001;141:e8
Bolger A (see Doehner et al). 2001;141:792-9
Bolognese L (see Santoro and Bolognese). 2001;141:S26-35
Borzanović M (see Maras et al). 2001;141:e8
Bosimini E (see Giannuzzi et al). 2001;141:131-8
Bourgoin P (see Logeart et al). 2001;141:247-53
Boyko V (see Fisman et al). 2001;141:485-90
Boyko V (see Rott et al). 2001;141:267-76
Boyko V (see Shotan et al). 2001;141:478-84
Bozovich GE (see Santopinto et al). 2001;141:566-72
Bransford TL (see Labovitz and Bransford). 2001;141:518-27
(Curriculum cardi.)
Braunwald E (see de Lemos et al). 2001;141:592-8
Braunwald E (see Giugliano et al). 2001;141:742-50
Braunwald E (see Wang-Clow et al). 2001;141:33-40
Brazaitis M (see Taylor et al). 2001;141:463-8
Breithardt O (see Ortlepp et al). 2001;141:671-6
Bricker JT (see Lai et al). 2001;141:661-70
Brieger D (see Eisenberg et al). 2001;141:837-46
Broderick TM (see Kereiakes et al). 2001;141:348-52
Brown DL (see Eisenberg et al). 2001;141:837-46
Brunotte F (see Cottin et al). 2001;141:999-1006
Brunsvig A (see Gullestad et al). 2001;141:418-21
Buckley A (see Mohammad et al). 2001;141:944-8
Budoff MJ (see Khaleeli et al). 2001;141:637-44
Buller CE (see Webb et al). 2001;141:964-70
Büller HR (see Fisher et al). 2001;141:26-32
Burke AP, Farb A, Malcom G, Virmani R. Effect of menopause on plaque morphologic characteristics in coronary atherosclerosis. 2001;141:S58-62
Burkert ML (see Kereiakes et al). 2001;141:348-52
Bussey H. Better delivery of standard antithrombotic care. 2001;141:1038-42 (Meetings)

C

- Cabell C (see O'Shea et al). 2001;141:306-18 (Meetings)
Cabell CH, Peterson GE. Factors affecting long-term mortality in endocarditis: The bugs, the drugs, the knife...or the patients? 2001;141:6-8 (Editorial)
Cadeddu C (see Colonna et al). 2001;141:S36-44
Caidahl K (see Karlson et al). 2001;141:977-84
Cairns JA, Hallstrom A, Held P. Should all trials have a Data Safety and Monitoring Committee? 2001;141:156-63 (Meetings)
Califf RM, Ellenberg SS. Statistical approaches and policies for the operations of Data and Safety Monitoring Committees. 2001; 141:301-5 (Meetings)
Califf RM, Lee KL. Data and safety monitoring committees: Philosophy and practice—Introduction. 2001;141:154-5 (Meetings)
Califf RM (see Cohen et al). 2001;141:391-401
Califf RM (see Labinaz et al). 2001;141:469-77
Califf RM (see O'Shea and Califf). 2001;141:864-5 (Meetings), 866-74 (Meetings), 875-80 (Meetings)
Califf RM (see Pilote et al). 2001;141:559-65
Califf RM (see Shah et al). 2001;141:528-35 (Trial design), xxx6
Callister TQ (see Raggi et al). 2001;141:375-82, 722-6 (Trial design)
Cannon CP (see Giugliano et al). 2001;141:742-50
Cannon CP (see Wang-Clow et al). 2001;141:33-40
Carere RG (see Webb et al). 2001;141:964-70
Cargill RI (see Mohammad et al). 2001;141:944-8
Carrozza JP (see Silva et al). 2001;141:353-9
Casalic C (see Santorelli et al). 2001;141:e1 (Prog. cardi.)
Caulin-Glaser T (see Clark et al). 2001;141:684-90
Cervesato E (see Giannuzzi et al). 2001;141:131-8
Chaisson CE (see Wang et al). 2001;141:957-63
Chambó JG (see Laguens et al). 2001;141:780-3
Chau K-t (see Cheung et al). 2001;141:87-91
Chen L (see Colonna et al). 2001;141:S36-44
Chen M (see Tulenko et al). 2001;141:S1-11
Chen Y-T, Wang Y, Radford MJ, Krumholz HM. Angiotensin-converting enzyme inhibitor dosages in elderly patients with heart failure. 2001;141:410-17
Cheng TO. Hippocrates and cardiology. 2001;141:173-83 (Curriculum cardi.)
Cheung Y-f, Leung MP, Chau K-t. Transcatheter closure of persistent arterial ducts with different types of coils. 2001;141:87-91
Chew P (see Albert et al). 2001;141:xxx6 (Trial design)
Chiarella F (see Cortigiani et al). 2001;141:621-9
Chierchia SL (see Sheiban et al). 2001;141:603-9
Chin AJ (see Fogel et al). 2001;141:630-6
Chittams J (see Packer et al). 2001;141:899-907
Chiu A (see Maisel et al). 2001;141:367-74
Cho L, Bhatt DL, Wolksi K, Lincoff M, Topol EJ, Moliterno DJ. Effect of smoking status and abciximab use on outcome after percutaneous coronary revascularization: Pooled analysis from EPIC, EPILOG, and EPISTENT. 2001;141:599-602
Chou TM (see Barron et al). 2001;141:933-9
Chough SP (see Sticherling et al). 2001;141:813-16
Christie DJ (see Madan et al). 2001;141:226-33
Clark DJ, Cleman MW, Pfau SE, Rollins SA, Ramahi TM, Mayer C, Caulin-Glaser T, Daher E, Kosiborod M, Bell L, Setaro JF. Serum complement activation in congestive heart failure. 2001;141:684-90
Clarke JA (see Nanthakumar et al). 2001;141:243-6
Cleman MW (see Clark et al). 2001;141:684-90
Clements IP, Miller WL. Effect of metoprolol on rest and exercise left ventricular systolic and diastolic function in idiopathic dilated cardiomyopathy. 2001;141:e5
Clopton P (see Greenon et al). 2001;141:447-55
Clopton P (see Maisel et al). 2001;141:367-74
Coats AJS (see Doehner et al). 2001;141:792-9
Cohen DJ (see Silva et al). 2001;141:353-9
Cohen EA (see Jong et al). 2001;141:218-25
Cohen MG, Pacchiana CM, Corbalán R, Isea Perez JE, Ponte CI, Silva Oropeza E, Diaz R, Paolasso E, Izasa D, Rodas MA, Urrutia CE, Harrington RA, Topol EJ, Califf RM. Variation in patient management and outcomes for acute coronary syndromes in Latin America and North America: Results from the Platelet IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial. 2001;141:391-401
Colan SD (see Lai et al). 2001;141:661-70
Coletta C (see Cortigiani et al). 2001;141:621-9
Colonna P, Cadeddu C, Chen L, Iliceto S. Clinical applications of contrast echocardiography. 2001;141:S36-44
Compton SJ (see Etheridge et al). 2001;141:105-10
Conti CR. Updated pathophysiologic concepts in unstable coronary artery disease. 2001;141:S12-14
Coil B (see Raggi et al). 2001;141:375-82
Corbalán R (see Cohen et al). 2001;141:391-401
Cortigiani L, Picano E, Coletta C, Chiarella F, Mathias W, Gandolfo N, De Alcantara M, Mazzoni V, Gensini GF, Landi P, Echo Persantine International Cooperative (EPIC) Study Group, Echo Dobutamine International Cooperative (EDIC) Study Group. Safety, feasibility, and prognostic implications of pharmacologic stress echocardiography in 1482 patients evaluated in an ambulatory setting. 2001;141:621-9
Cottin Y, Rezaizadeh K, Touzery C, Barillot I, Zeller M, Prevot S, L'Huillier I, Ressenecourt O, André F, Fraison M, Louis P, Brunotte F, Wolf JE. Long-term prognostic value of ²⁰¹Tl single-photon emission computed tomographic myocardial perfusion imaging after coronary stenting. 2001;141:999-1006
Coussement P (see de Lemos et al). 2001;141:592-8
Cowan LD (see Devereux et al). 2001;141:439-46
Coyle LC (see Markwood et al). 2001;141:342-7 (Trial design)

- Craig JE (see Etheridge et al). 2001;141:105-10
Crawford MH (see O'Connell et al). 2001;141:254-8
Criger DA (see Birnbaum et al). 2001;141:915-24
Crijs HJGM (see Amoroso et al). 2001;141:522-5
Cusson C (see Logeart et al). 2001;141:247-53

D

- Daher E (see Clark et al). 2001;141:684-90
Dahlöf B (see Palmieri et al). 2001;141:784-91
Dal Bó CMR (see Mansur et al). 2001;141:78-86
d'Amati G (see Santorelli et al). 2001;141:e1 (Prog. cardiol.)
Damiani A (see Lanza et al). 2001;141:808-12
Danays T (see Wang-Clow et al). 2001;141:33-40
Dandreo K (see Silva et al). 2001;141:353-9
Dangas G (see DeGeare et al). 2001;141:15-24 (Curriculum cardiol.)
Dangas G (see Mehran et al). 2001;141:610-14
Dargie HJ (see Murdoch et al). 2001;141:800-7
Davidson M (see Raggi et al). 2001;141:722-6 (Trial design)
Davies A (see Sutton et al). 2001;141:677-83
Davies GJ (see Tousoulis et al). 2001;141:277-80
Davos CH (see Doehner et al). 2001;141:792-9
De Alcantara M (see Cortigiani et al). 2001;141:621-9
de Belder AJ (see Nageh et al). 2001;141:971-6
de Belder MA (see Sutton et al). 2001;141:677-83
De Franco AC (see Ziada et al). 2001;141:823-31
de Lemos JA, Gibson CM, Antman EM, Murphy SA, Morrow DA, Schuhwerk KC, Schweiger M, Coussement P, Van de Werf F, Braunwald E, TIMI 14 Investigators. Abciximab and early adjunctive percutaneous coronary intervention are associated with improved ST-segment resolution after thrombolysis: Observations from the TIMI 14 Trial. 2001;141:592-8
De Luca L (see Lanza et al). 2001;141:808-12
De Maria A (see Maisel et al). 2001;141:367-74
De Martino G (see Lanza et al). 2001;141:808-12
de Simone G (see Palmieri et al). 2001;141:784-91
DeGeare VS, Dangas G, Stone GW, Grines CL. Interventional procedures in acute myocardial infarction. 2001;141:15-24 (Curriculum cardiol.)
Dehmer GJ (see Raymond et al). 2001;141:435-8
Del Core M (see Eisenberg et al). 2001;141:837-46
Deliargyris EN (see Raymond et al). 2001;141:435-8
Deligonul U (see Eisenberg et al). 2001;141:837-46
Dello Russo A (see Lanza et al). 2001;141:808-12
Dello Russo G (see Pitzalis et al). 2001;141:765-71
DeLoof M (see Kereiakes et al). 2001;141:348-52
DeMets DL, Yusuf S. The Data and Safety Monitoring Committee: Some final thoughts. 2001;141:548-9 (Meetings)
Devereux RB, Roman MJ, Parancas M, Lee ET, Welty TK, Fabsitz RR, Robbins D, Rhoades ER, Rodeheffer RJ, Cowan LD, Howard BV. A population-based assessment of left ventricular systolic dysfunction in middle-aged and older adults: The Strong Heart Study. 2001;141:439-46
Devereux RB (see Ilıcil et al). 2001;141:992-8
Devereux RB (see Palmieri et al). 2001;141:784-91
Devereux RB (see Vakili et al). 2001;141:334-41 (Prog. cardiol.)
Dewhurst T (see Spertus et al). 2001;141:550-8
Diaz R (see Cohen et al). 2001;141:391-401
Dietz R (see Wassmuth et al). 2001;141:1007-13
Direct Thrombin Inhibitor Trialists' Collaborative Group. Direct thrombin inhibitors in acute coronary syndromes and during percutaneous coronary intervention: Design of a meta-analysis based on individual patient data. 2001;141:e2 (Trial design)
Doba N (see Tomiyama et al). 2001;141:422-7
Doehner W, Rauchhaus M, Florea VG, Sharma R, Bolger A, Davos CH, Coats AJS, Anker SD. Uric acid in cachectic and

- noncachectic patients with chronic heart failure: Relationship to leg vascular resistance. 2001;141:792-9
Doerken B (see Wassmuth et al). 2001;141:1043-7
D'Orsogna L (see Papagiannis et al). 2001;141:491-9
Dougherty CM (see Spertus et al). 2001;141:550-8
Duerr R (see Eisenberg et al). 2001;141:837-46
Dyke CK (see McGuire et al). 2001;141:164-72 (Meetings)
Dyke CK (see O'Shea et al). 2001;141:306-18 (Meetings)

E

- Eagle KA (see Kim and Eagle). 2001;141:691-3 (Editorial)
Easley KA (see Lai et al). 2001;141:661-70
East MA (see O'Shea et al). 2001;141:306-18 (Meetings)
Echo Dobutamine International Cooperative (EDIC) Study Group (see Cortigiani et al). 2001;141:621-9
Echo Persantine International Cooperative (EPIC) Study Group (see Cortigiani et al). 2001;141:621-9
Edmunds LH Jr. Evolution of prosthetic heart valves. 2001;141:849-55 (Meetings)
Eisenberg MJ, Schechter D, Lefkowitz J, Goudreau E, Deligonul U, Mak K-H, Del Core M, Duerr R, Garzon PM, Huynh T, Smilovitch M, Sedlis S, Brown DL, Brieger D, Pilote L, ROSETTA Investigators. Use of routine functional testing after percutaneous transluminal coronary angioplasty: Results from the ROSETTA Registry. 2001;141:837-46
Eisenberg P (see Becker et al). 2001;141:1025-37 (Meetings)
Ellenberg SS (see Califf and Ellenberg). 2001;141:301-5 (Meetings)
Ellis SG (see Labinaz et al). 2001;141:469-77
Ellis SG (see Ziada et al). 2001;141:823-31
Endo T (see Kosuge et al). 2001;141:759-64
Erdbruegger U (see Wassmuth et al). 2001;141:1007-13
ESCAPE Investigators (see Shah et al). 2001;141:528-35 (Trial design)
Etheridge SP, Craig JE, Compton SJ. Amiodarone is safe and highly effective therapy for supraventricular tachycardia in infants. 2001;141:105-10
Every NR (see Barron et al). 2001;141:933-9
Every NR (see Kim et al). 2001;141:73-7
Exner DV, Sheldon RS, Pinski SL, Kron J, Hallstrom A, AVID Investigators. Do baseline characteristics accurately discriminate between patients likely versus unlikely to benefit from implantable defibrillator therapy? 2001;141:99-104

F

- Fabsitz RR (see Devereux et al). 2001;141:439-46
Fabsitz RR (see Ilıcil et al). 2001;141:992-8
Farb A (see Burke et al). 2001;141:558-62
Farmer R (see Murdoch et al). 2001;141:800-7
Fathi R, Marwick TH. Noninvasive tests of vascular function and structure: Why and how to perform them. 2001;141:694-703 (Prog. cardiol.)
Faughnan ME (see Nanthakumar et al). 2001;141:243-6
Feinberg MS (see Rott et al). 2001;141:267-76
Ferdinand FD (see Tulenko et al). 2001;141:S1-11
Ferlin EL (see Ribeiro et al). 2001;141:260-5
Feuerstein I (see Taylor et al). 2001;141:463-8
Feuerstein IM (see Hunt et al). 2001;141:206-10
Finn P (see Sutton et al). 2001;141:677-83
Fioretti A (see Pitzalis et al). 2001;141:765-71
Fisher L, Klibaner M. Regulatory issues for Data and Safety Monitoring Committees. 2001;141:536-41 (Meetings)
Fisher LD, Gent M, Büller HR. Active-control trials: How would a new agent compare with placebo? A method illustrated with clopidogrel, aspirin, and placebo. 2001;141:26-32

- Fisman EZ, Motro M, Tenenbaum A, Boyko V, Mandelzweig L, Behar S. Impaired fasting glucose concentrations in nondiabetic patients with ischemic heart disease: A marker for a worse prognosis. 2001;141:485-90
- Fitzgerald R (see Greenon et al). 2001;141:447-55
- Flaherty PJ (see Markwood et al). 2001;141:342-7 (Trial design)
- Flather MD (see Shibata et al). 2001;141:1019-24 (Meetings)
- Flink H (see Bjessmo et al). 2001;141:9-14 (Curriculum cardiol.)
- Florez VG (see Doeheer et al). 2001;141:792-9
- Fogel MA, Rychik J, Chin AJ, Hubbard A, Weinberg PM. Evaluation and follow-up of patients with left ventricular apical to aortic conduits with 2D and 3D magnetic resonance imaging and Doppler echocardiography: A new look at an old operation. 2001;141:630-6
- Fox NL (see Wang-Clow et al). 2001;141:33-40
- Fragasso G (see Sheiban et al). 2001;141:603-9
- Fraison M (see Cottin et al). 2001;141:999-1006
- Francis GS. Aldosterone inhibition and heart failure: Too good to be true? 2001;141:1-2 (Editorial)
- Franco I (see Ziada et al). 2001;141:823-31
- Frank H. Characterization of atherosclerotic plaque by magnetic resonance imaging. 2001;141:54-8
- French JK (see Amos et al). 2001;141:586-91
- Friedrich MG (see Wassmuth et al). 2001;141:1007-13
- Frilling B, Schiele R, Gitt AK, Zahn R, Schneider S, Glunz H-G, Gieseler U, Baumgärtel B, Asbeck F, Senges J. Maximal Individual Therapy in Acute Myocardial Infarction (MITRA) Study Group. Myocardial Infarction Registry (MIR) Study Group. Characterization and clinical course of patients not receiving aspirin for acute myocardial infarction: Results from the MITRA and MIR studies. 2001;141:200-5
- Froland SS (see Gullestad et al). 2001;141:418-21
- Fry E (see Kereiakes et al). 2001;141:348-52
- Fukushi T (see Inokubo et al). 2001;141:211-17
- Fukushima JT (see Mansur et al). 2001;141:78-86
- Fumagalli G (see Lanza et al). 2001;141:808-12
- Furberg CD (see Pocock and Furberg). 2001;141:289-94 (Meetings)

G

- Galanos A (see Gattis et al). 2001;141:331-3 (Editorial)
- Gandolfo N (see Cortigiani et al). 2001;141:621-9
- Ganesalingam R (see Kamath et al). 2001;141:e3 (Letter)
- Garcia A (see Maisel et al). 2001;141:367-74
- Gardetto N (see Maisel et al). 2001;141:367-74
- Garratt KN (see Hasdai et al). 2001;141:117-23
- Garzon PM (see Eisenberg et al). 2001;141:837-46
- Gates K (see Birnbaum et al). 2001;141:915-24
- Gattis WA, Galanos A, O'Connor CM. Angiotensin-converting enzyme inhibitor dosing in heart failure: What is optimal? 2001;141:331-3 (Editorial)
- Gemitzis KD (see Karvounis et al). 2001;141:e7
- Genest J Jr (see McPherson et al). 2001;141:949-56
- Gensini GF (see Cortigiani et al). 2001;141:621-9
- Gent M (see Fisher et al). 2001;141:26-32
- Gentile F (see Giannuzzi et al). 2001;141:131-8
- George BS (see Silva et al). 2001;141:353-9
- Geraci E (see Giannuzzi et al). 2001;141:131-8
- Gerasimidou I (see Hahalis et al). 2001;141:428-34
- Gerdts E (see Palmieri et al). 2001;141:784-91
- Gersh BJ (see Rathore et al). 2001;141:47-54
- Gheorghide M (see Shah et al). 2001;141:908-14
- Giannuzzi P, Temporelli PL, Bosimini E, Gentile F, Lucci D, Maggioni AP, Tavazzi L, Badano L, Stoian I, Piazza R, Heyman I, Levantesi G, Cervasato E, Geraci E, Nicolosi GL. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-3 Echo Substudy Investigators. Heterogeneity of left ventricular remodeling after acute myocardial infarction:

- Results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-3 Echo Substudy. 2001;141:131-8
- Gibson CM (see Angeja and Gibson). 2001;141:329-30 (Editorial)
- Gibson CM (see de Lemos et al). 2001;141:592-8
- Gibson CM (see Wang-Clow et al). 2001;141:33-40
- Gieseler U (see Frilling et al). 2001;141:200-5
- Giglio V (see Lanza et al). 2001;141:808-12
- Gimple LW (see Ragosta et al). 2001;141:456-62
- Gitt AK (see Frilling et al). 2001;141:200-5
- Giugliano RP, McCabe CH, Antman EM, Cannon CP, Van de Werf F, Wilcox RG, Braunwald E. Thrombolysis in Myocardial Infarction (TIMI) Investigators. Lower-dose heparin with fibrinolysis is associated with lower rates of intracranial hemorrhage. 2001;141:742-50
- Glassberg HL (see Guazzi et al). 2001;141:139-47
- Glazer S (see Madan et al). 2001;141:226-33
- Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO-I) Investigators (see Topol et al). 2001;141:559-65
- Glunz H-G (see Frilling et al). 2001;141:200-5
- Gold JM (see Shammash et al). 2001;141:148-53
- Gold M (see Kron et al). 2001;141:92-8
- Goldberg RJ, Gore JM, Thompson CA, Gurwitz JH. Recent magnitude of and temporal trends (1994-1997) in the incidence and hospital death rates of cardiogenic shock complicating acute myocardial infarction: The second National Registry of Myocardial Infarction. 2001;141:65-72
- Goldberg RJ (see Barron et al). 2001;141:933-9
- Goldbourt U (see Shatan et al). 2001;141:478-84
- Golden MA (see Shammash et al). 2001;141:148-53
- Goldman I (see Tsevat et al). 2001;141:727-34
- Goldner B (see Kron et al). 2001;141:92-8
- Gore JM (see Barron et al). 2001;141:933-9
- Gore JM (see Goldberg et al). 2001;141:65-72
- Gottlieb S (see Rott et al). 2001;141:267-76
- Gottlieb S (see Shatan et al). 2001;141:478-84
- Goudreau E (see Eisenberg et al). 2001;141:837-46
- GRACE Investigators. Rationale and design of the GRACE (Global Registry of Acute Coronary Events) Project: A multinational registry of patients hospitalized with acute coronary syndromes. 2001;141:190-9 (Trial design)
- Graham AT (see Nanthakumar et al). 2001;141:243-6
- Grande P (see Nanthakumar et al). 2001;141:243-6
- Granger CB (see Birnbaum et al). 2001;141:915-24
- Greaves SC (see Aikawa et al). 2001;141:234-42
- Grech ED (see Sutton et al). 2001;141:677-83
- Greeley WJ (see Schreiner and Greeley). 2001;141:3-5 (Editorial)
- Greenberg S (see Weaver and Greenberg). 2001;141:295-300 (Meetings)
- Greenon N, Macoviak J, Krishnaswamy P, Morrissey R, James C, Clopton P, Fitzgerald R, Maisel AS. Usefulness of cardiac troponin I in patients undergoing open heart surgery. 2001;141:447-55
- Grill DE (see Hasdai et al). 2001;141:117-23
- Grinberg M (see Mansur et al). 2001;141:78-86
- Grines CL (see DeGare et al). 2001;141:15-24 (Curriculum cardiol.)
- Grossman E (see Sharabi et al). 2001;141:1014-7
- Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-3 Echo Substudy Investigators (see Giannuzzi et al). 2001;141:131-8
- Guazzi M, Musante FC, Glassberg HL, Libonati JR. Detection of changes in diastolic function by pulmonary venous flow analysis in women athletes. 2001;141:139-47
- Guida P (see Pitzalis et al). 2001;141:765-71
- Guiti C (see Logeart et al). 2001;141:247-53
- Gullestad L, Ueland T, Brunsvig A, Kjekshus J, Simonsen S, Froland SS, Aukrust P. Effect of metoprolol on cytokine levels in chronic heart failure—A substudy in the Metoprolol

- Controlled-Release Randomised Intervention Trial in Heart Failure (MERIT-HF). 2001;141:418-21
 Gurfinkel EP (see Laguens et al). 2001;141:780-3
 Gurfinkel EP (see Santopinto et al). 2001;141:566-72
 Gurwitz JH (see Goldberg et al). 2001;141:65-72
 GUSTO-I Investigators (see Labinaz et al). 2001;141:469-77

H

- Hahalis G, Manolis AS, Gerasimidou I, Alexopoulos D, Sifafidis G, Kourakli A, Körfer R, Koerner MM, Vagenakis AG, Zoumbos NC. Right ventricular diastolic function in β -thalassaemia major: Echocardiographic and clinical correlates. 2001;141:428-34
 Hall JA (see Sutton et al). 2001;141:677-83
 Hallstrom A (see Cairns et al). 2001;141:156-63 (Meetings)
 Hallstrom A (see Exner et al). 2001;141:99-104
 Halperin B (see Kron et al). 2001;141:92-8
 Hameed A (see Baruch et al). 2001;141:e6
 Hammar N (see Bjessmo et al). 2001;141:9-14 (Curriculum cardi-
 diol.)
 Hanada H (see Inokubo et al). 2001;141:211-17
 Hanin A (see Sharabi et al). 2001;141:1014-7
 Hanrath P (see Ortlepp et al). 2001;141:671-6
 Hara K (see Kozuma et al). 2001;141:124-30
 Harada H (see Lee et al). 2001;141:184-9 (Prog. cardi-
 ol.)
 Harrington RA (see Cohen et al). 2001;141:391-401
 Harris L (see Bar-Or et al). 2001;141:985-91
 Hasdai D, Rizza RA, Grill DE, Scott CG, Garratt KN, Holmes DR Jr. Glycemic control and outcome of diabetic patients after successful percutaneous coronary revascularization. 2001; 141:117-23
 Hassapopoulos EP (see Karvounis et al). 2001;141:e7
 Hasselblad V (see Shah et al). 2001;141:528-35 (Trial design)
 Hata K (see Kawai et al). 2001;141:925-32
 Hatada K (see Tsuka et al). 2001;141:615-20
 Held P (see Cairns et al). 2001;141:156-63 (Meetings)
 Henrion D (see Kennedy et al). 2001;141:e4 (Letter)
 Herlitz J (see Karlson et al). 2001;141:977-84
 Herre J (see Kron et al). 2001;141:92-8
 Hetzel FW (see Bar-Or et al). 2001;141:985-91
 Heyman I (see Giannuzzi et al). 2001;141:131-8
 Hochman JS (see Ohman and Hochman). 2001;141:889-92 (Editorial)
 Hochman JS (see Webb et al). 2001;141:964-70
 Hod H (see Rott et al). 2001;141:267-76
 Hod H (see Shotan et al). 2001;141:478-84
 Hoffer E (see Lancellotti et al). 2001;141:772-9
 Hoffmann R (see Ortlepp et al). 2001;141:671-6
 Holmes DR Jr (see Hasdai et al). 2001;141:117-23
 Holmes DR Jr (see Labinaz et al). 2001;141:469-77
 Holmes DR Jr (see Wilson et al). 2001;141:704-10 (Prog. cardi-
 ol.)
 Holubkov R (see Reis et al). 2001;141:735-41
 Homaei H (see Tousoulis et al). 2001;141:277-80
 Hong M-K, Park S-W, Lee CW, Rhee K-S, Song J-M, Kang D-H, Song J-K, Kim J-J, Park S-J. Six-month angiographic follow-up after intravascular ultrasound-guided stenting of infarct-related artery: Comparison with non-infarct-related artery. 2001; 141:832-6
 Hongo Y (see Kosuge et al). 2001;141:759-64
 Horwood L (see Sticherling et al). 2001;141:813-16
 Houghtaling PL (see Ziada et al). 2001;141:823-31
 Howard BV (see Devereux et al). 2001;141:439-46
 Howard BV (see Ilter et al). 2001;141:992-8
 Huang Y (see Tulenko et al). 2001;141:51-11
 Hubbard A (see Fogel et al). 2001;141:630-6
 Hudson MP (see McGuire et al). 2001;141:164-72 (Meetings)
 Hunt ME, O'Malley PG, Vernalis MN, Feuerstein IM, Taylor AJ. C-

- reactive protein is not associated with the presence or extent of calcified subclinical atherosclerosis. 2001;141:206-10
 Hutchison SJ (see Nanthakumar et al). 2001;141:243-6
 Huynh T (see Eisenberg et al). 2001;141:837-46
 Hwang TH (see Lee et al). 2001;141:184-9 (Prog. cardi-
 ol.)
 Hyland RH (see Nanthakumar et al). 2001;141:243-6

I

- Iacoviello M (see Pitzalis et al). 2001;141:765-71
 Ikari Y (see Kozuma et al). 2001;141:124-30
 Ilteril A, Devereux RB, Roman MJ, Parancas M, O'Grady MJ, Welty TK, Robbins DC, Fabsitz RR, Howard BV, Lee ET. Relationship of impaired glucose tolerance to left ventricular structure and function: The Strong Heart Study. 2001;141:992-8
 Illiceto S (see Colonna et al). 2001;141:536-44
 Inokubo Y, Hanada H, Ishizaka H, Fukushi T, Kamada T, Okumura K. Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome. 2001;141:211-17
 Inoue A (see Yamazaki et al). 2001;141:645-52
 INTER-HEART Investigators (see Öunpuu et al). 2001;141:711-21 (Prog. cardi-
 ol.)
 Isea Perez JE (see Cohen et al). 2001;141:391-401
 Ishikawa K (see Kachi et al). 2001;141:55-64
 Ishikawa T (see Kosuge et al). 2001;141:759-64
 Ishizaka H (see Inokubo et al). 2001;141:211-17
 Israel Thrombolytic Survey Group (see Shotan et al). 2001;141:478-84
 Issa VS (see Mansur et al). 2001;141:78-86
 Ivert T (see Bjessmo et al). 2001;141:9-14 (Curriculum cardi-
 ol.)
 Iwasaka T (see Tsuka et al). 2001;141:615-20
 Izasa D (see Cohen et al). 2001;141:391-401

J

- James C (see Greenon et al). 2001;141:447-55
 Jennings LK (see Madan et al). 2001;141:226-33
 Jesse RL (see Kontos et al). 2001;141:360-6
 Joint European Societies Task Force (see Wood and Joint European Societies Task Force). 2001;141:S49-57
 Jong P, Cohen EA, Batchelor W, Lazzam C, Kreatsoulas C, Natarajan MK, Strauss BH. Bleeding risks with abciximab after full-dose thrombolysis in rescue or urgent angioplasty for acute myocardial infarction. 2001;141:218-25
 Jovanović T (see Maras et al). 2001;141:e8

K

- Kabano T (see Yamazaki et al). 2001;141:645-52
 Kachi E, Yoshino H, Watanuki A, Sasaki K, Sakata K, Ishikawa K. Effect of the stenosis location and severity on left ventricular function after single-vessel anterior wall myocardial infarction. 2001;141:55-64
 Kafonek S (see Raggi et al). 2001;141:722-6 (Trial design)
 Kallfelz C (see Papagiannis et al). 2001;141:491-9
 Kamada T (see Inokubo et al). 2001;141:211-17
 Kamath S, Yunus F, Ganesalingam R, Lip GH. Diurnal variation and cardiovascular disease. 2001;141:e3 (Letter)
 Kamiyama T (see Kato et al). 2001;141:940-3
 Kang D-H (see Hong et al). 2001;141:832-6
 Kapadia SR (see Ziada et al). 2001;141:823-31
 Kaplan S (see Lai et al). 2001;141:661-70

- Kapinsky E (see Rott et al). 2001;141:267-76
- Kapinsky E (see Shotan et al). 2001;141:478-84
- Karas RH (see Kuvin et al). 2001;141:327-8 (Editorial)
- Karlson BW, Sjölin M, Lindqvist J, Caidahl K, Herlitz J. Ten-year mortality rate in relation to observations at a bicycle exercise test in patients with a suspected or confirmed ischemic event but no or only minor myocardial damage: Influence of subsequent revascularization. 2001;141:977-84
- Karvounis HI, Zaglavara TA, Parharidis GE, Nouskas IG, Hassapopoulou EP, Gemitzis KD, Louridas GE. An angiotensin-converting enzyme inhibitor improves left ventricular systolic and diastolic function in transfusion-dependent patients with β -thalassemia major. 2001;141:e7
- Kato T, Kamiyama T, Maruyama Y, Tanaka S, Yoshimoto N. Nicorandil, a potent cardioprotective agent, reduces QT dispersion during coronary angioplasty. 2001;141:940-3
- Kaul A (see O'Shea et al). 2001;141:306-18 (Meetings)
- Kawai H (see Kawai et al). 2001;141:925-32
- Kawai K, Hata K, Takaoka H, Kawai H, Yokoyama M. Plasma brain natriuretic peptide as a novel therapeutic indicator in idiopathic dilated cardiomyopathy during β -blocker therapy: A potential of hormone-guided treatment. 2001;141:xxx8
- Kazemoglu R (see Maisel et al). 2001;141:367-74
- Kelsey SF (see Reis et al). 2001;141:735-41
- Kennedy JH, Henrion D, Wassef M, Bloch G, Tedgui A. Cytomegalovirus in calcific aortic valves. 2001;141:e4 (Letter)
- Kent KM (see Mehran et al). 2001;141:610-14
- Kent SM (see Markwood et al). 2001;141:342-7 (Trial design)
- Kereiakes DJ, Kleiman NS, Fry E, Mwawasi G, Lengerich R, Maresh K, Burkert ML, Aquilina JW, DeLoof M, Broderick TM, Shimshak TM. Dalteparin in combination with abciximab during percutaneous coronary intervention. 2001;141:348-52
- Kervinen H, Palosuo T, Manninen V, Tenkanen L, Vaarala O, Mänttari M. Joint effects of C-reactive protein and other risk factors on acute coronary events. 2001;141:580-5
- Khaleeli E, Peters SR, Bobrowsky K, Oudiz RJ, Ko JY, Budoff MJ. Diabetes and the associated incidence of subclinical atherosclerosis and coronary artery disease: Implications for management. 2001;141:637-44
- Kim C, Schaaf CH, Maynard C, Every NR. Unstable angina in the Myocardial Infarction Triage and Intervention Registry (MITI): Short- and long-term outcomes in men and women. 2001;141:73-7
- Kim J-J (see Hong et al). 2001;141:832-6
- Kim MH, Eagle KA. Postoperative atrial fibrillation after heart surgery: What are the goals of prevention? 2001;141:691-3 (Editorial)
- Kim MH (see Sticherling et al). 2001;141:813-16
- Kimmel SE (see Shammash et al). 2001;141:148-53
- Kimura A (see Lee et al). 2001;141:184-9 (Prog. cardiol.)
- Kimura K (see Kosuge et al). 2001;141:759-64
- Kjekshus J (see Gullestad et al). 2001;141:118-21
- Kleiman NS (see Kereiakes et al). 2001;141:348-52
- Klein GJ (see Kohn et al). 2001;141:111-16, 817-21
- Klibaner M (see Fisher and Klibaner). 2001;141:536-41 (Meetings)
- Knight BP (see Sticherling et al). 2001;141:813-16
- Ko JY (see Khaleeli et al). 2001;141:637-44
- Koerner MM (see Hahalis et al). 2001;141:428-34
- Koller PT (see Webb et al). 2001;141:964-70
- Konstant MA (see Packer et al). 2001;141:899-907
- Kontos MC, Kurdziel KA, Ornato JP, Schmidt KL, Jesse RL, Tatum JL. A nonischemic electrocardiogram does not always predict a small myocardial infarction: Results with acute myocardial perfusion imaging. 2001;141:360-6
- Koon J (see Maisel et al). 2001;141:367-74
- Körfer R (see Hahalis et al). 2001;141:428-34
- Kosiborod M (see Clark et al). 2001;141:684-90
- Kosuge M, Kimura K, Ishikawa T, Endo T, Shimizu M, Hongo Y, Okuda J, Tochikubo O, Umemura S. Early peak creatine kinase activity is not always a marker of successful reperfusion with myocardial salvage in patients with reperfused anterior acute myocardial infarction. 2001;141:759-64
- Kourakli A (see Hahalis et al). 2001;141:428-34
- Kovačević S (see Maras et al). 2001;141:e8
- Kozuma K, Hara K, Yamasaki M, Morino Y, Ayabe S, Kuroda Y, Tanabe K, Ikari Y, Tamura T. Effects of cilostazol on late lumen loss and repeat revascularization after Palmaz-Schatz coronary stent implantation. 2001;141:124-30
- Krahn AD, Klein GJ, Yee R, Skanes AC, Reveal Investigators. Predictive value of presyncope in patients monitored for assessment of syncope. 2001;141:817-21
- Krahn AD, Nguyen-Ho P, Klein GJ, Yee R, Skanes AC, Suskin N. QT dispersion: An electrocardiographic derivative of QT prolongation. 2001;141:111-16
- Kreatsoulas C (see Jong et al). 2001;141:218-25
- Krishnaswamy P (see Greenon et al). 2001;141:447-55
- Krishnaswamy P (see Maisel et al). 2001;141:367-74
- Kron J, Herre J, Renfro EG, Rizo-Patron C, Raitt M, Halperin B, Gold M, Goldner B, Wathen M, Wilkoff B, Olarte A, Yao Q, AVID Investigators. Lead- and device-related complications in the Antiarrhythmics Versus Implantable Defibrillators Trial. 2001;141:92-8
- Kron J (see Exner et al). 2001;141:99-104
- Krumholz HM (see Chen et al). 2001;141:410-17
- Kugiyama K (see Nishiyama et al). 2001;141:e9
- Kulbertus HE (see Lancellotti et al). 2001;141:772-9
- Kuntz KM (see Tsevat et al). 2001;141:727-34
- Kuntz RE (see Silva et al). 2001;141:353-9
- Kurdziel KA (see Kontos et al). 2001;141:360-6
- Kuroda Y (see Kozuma et al). 2001;141:124-30
- Kuvin JT, Patel AR, Karas RH. Need for standardization of noninvasive assessment of vascular endothelial function. 2001;141:327-8 (Editorial)

L

- Labinaz M, Sketch MH Jr, Ellis SG, Abramowitz BM, Stebbins AL, Pieper KS, Holmes DR Jr, Calif RM, Topol EJ, GUSTO-I Investigators. Outcome of acute ST-segment elevation myocardial infarction in patients with prior coronary artery bypass surgery receiving thrombolytic therapy. 2001;141:469-77
- Labovitz AJ, Bransford TL. Evolving role of echocardiography in the management of atrial fibrillation. 2001;141:518-27 (Curriculum cardi.)
- Laguens RP, Vigliano CA, Macchia A, Argel MI, Chambó JG, Gurfinkel EP. Anti-human skeletal muscle glycolipid antibodies in unstable angina. 2001;141:780-3
- Lai WW, Colan SD, Easley KA, Lipshultz SE, Starc TJ, Bricker JT, Kaplan S, P²C² HIV Study Group. Dilatation of the aortic root in children infected with human immunodeficiency virus type 1: The Prospective P²C² HIV Multicenter Study. 2001;141:661-70
- Lancellotti P, Seidel L, Hoffer E, Kulbertus HE, Piérard LA. Exercise versus dobutamine-induced ST elevation in the infarct-related electrocardiographic leads: Clinical significance and correlation with functional recovery. 2001;141:772-9
- Landi P (see Cortigiani et al). 2001;141:621-9
- Lansky AA (see Silva et al). 2001;141:353-9
- Lansky AJ (see Mehran et al). 2001;141:610-14
- Lanza GA, Dello Russo A, Giglio V, De Luca L, Messano L, Santini C, Ricci E, Damiani A, Fumagalli G, De Martino G, Mangiola F, Bellocchi F. Impairment of cardiac autonomic function in patients with Duchenne muscular dystrophy: Relationship to myocardial and respiratory function. 2001;141:808-12
- Laskey R (see Raggi et al). 2001;141:722-6 (Trial design)
- Lau E (see Bar-Or et al). 2001;141:985-91
- Laury-Kleintop L (see Tulenko et al). 2001;141:S1-11
- Lazzam C (see Jong et al). 2001;141:218-25

- Leban M (see Logeart et al). 2001;141:247-53
- Lee CW (see Hong et al). 2001;141:832-6
- Lee ET (see Devereux et al). 2001;141:439-46
- Lee ET (see Iltercil et al). 2001;141:992-8
- Lee KL (see Califf and Lee). 2001;141:154-5 (Meetings)
- Lee RT (see Aikawa et al). 2001;141:234-42
- Lee W-H, Hwang TH, Kimura A, Park SW, Satoh M, Nishi H, Harada H, Toyama J, Park J-E. Different expressivity of a ventricular essential myosin light chain gene Ala57Gly mutation in familial hypertrophic cardiomyopathy. 2001;141:184-9 (Prog. cardiol.)
- Leffkovits J (see Eisenberg et al). 2001;141:837-46
- Lengerich R (see Kereiakes et al). 2001;141:348-52
- Lentzsch S (see Wassmuth et al). 2001;141:xx20
- Leon MB (see Mehran et al). 2001;141:610-14
- Lerman BB (see Stein et al). 2001;141:282-8
- Leung MP (see Cheung et al). 2001;141:87-91
- Levantesi G (see Giannuzzi et al). 2001;141:131-8
- Levine RA (see Mele et al). 2001;141:653-60
- Levy JH. Novel intravenous antithrombins. 2001;141:1043-7 (Meetings)
- Lévy S. Pharmacologic management of atrial fibrillation: Current therapeutic strategies. 2001;141:S15-21
- L'Huillier I (see Cottin et al). 2001;141:999-1006
- Libonati JR (see Guazzi et al). 2001;141:139-47
- Lincoff M (see Cho et al). 2001;141:599-602
- Lindqvist J (see Karlson et al). 2001;141:977-84
- Linnaluoto M (see Ylitalo et al). 2001;141:e10
- Lip GYH (see Kamath et al). 2001;141:e3 (Letter)
- Lipshultz SE (see Lai et al). 2001;141:661-70
- Logeart D, Beyne P, Cusson C, Tokmakova M, Leban M, Guiti C, Bourgoin P, Söfal AC. Evidence of cardiac myolysis in severe nonischemic heart failure and the potential role of increased wall strain. 2001;141:247-53
- Loh E (see Baruch et al). 2001;141:e6
- Louis P (see Cottin et al). 2001;141:999-1006
- Louridas GE (see Karvounis et al). 2001;141:e7
- Lu C (see Sheiban et al). 2001;141:603-9
- Lucci D (see Giannuzzi et al). 2001;141:131-8
- M**
- Macchia A (see Laguens et al). 2001;141:780-3
- Macvial J (see Greenson et al). 2001;141:447-55
- Madan M, Berkowitz SD, Christie DJ, Jennings LK, Smit AC, Sigmon KN, Glazer S, Tcheng JE. Rapid assessment of glycoprotein IIb/IIIa blockade with the platelet function analyzer (PFA-100) during percutaneous coronary intervention. 2001;141:226-33
- Mager A (see Birnbaum et al). 2001;141:915-24
- Maggioni AP (see Giannuzzi et al). 2001;141:131-8
- Mahaffey KW, Alpert JS. Cardiac enzyme elevations after cardiac surgery: The cardiologist's perspective. 2001;141:321-4 (Editorial)
- Mahy IR (see Mohammad et al). 2001;141:944-8
- Maisel AS, Koon J, Krishnaswamy P, Kazenegra R, Clopton P, Gardetto N, Morrissey R, Garcia A, Chiu A, De Maria A. Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. 2001;141:367-74
- Maisel AS (see Greenson et al). 2001;141:447-55
- Mak K-H (see Eisenberg et al). 2001;141:837-46
- Malcom G (see Burke et al). 2001;141:858-62
- Manda SOM (see Amos et al). 2001;141:586-91
- Mandelzweig I (see Fisman et al). 2001;141:485-90
- Mandelzweig I (see Rott et al). 2001;141:267-76
- Mandelzweig I (see Shotan et al). 2001;141:478-84
- Mandzia JL (see Nanthakumar et al). 2001;141:243-6
- Mangiola F (see Lanza et al). 2001;141:808-12
- Manninen V (see Kervinen et al). 2001;141:580-5
- Manolis AS (see Hahalis et al). 2001;141:428-34
- Mansur AJ, Dal Bó CMR, Fukushima JT, Issa VS, Grinberg M, Pomerantzeff PMA. Relapses, recurrences, valve replacements, and mortality during the long-term follow-up after infective endocarditis. 2001;141:78-86
- Mänttari M (see Kervinen et al). 2001;141:580-5
- Maraš D, Bošković SD, Popović Z, Nešković AN, Kovačević S, Otašević P, Marinković J, Vuk L, Borzanović M, Nastasić S, Jovanović T, Bojić M, Babić R, Popović AD. Single-day loading dose of oral amiodarone for the prevention of new-onset atrial fibrillation after coronary artery bypass surgery. 2001;141:e8
- Marcos E (see Santopinto et al). 2001;141:566-72
- Marash K (see Kereiakes et al). 2001;141:348-52
- Marinković J (see Maraš et al). 2001;141:e8
- Markowitz SM (see Stein et al). 2001;141:282-8
- Markwood TT, Kent SM, Coyle LC, Flaherty PJ, O'Malley PG, Taylor AJ. Design and rationale of the ARBITER trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol)—A randomized trial comparing the effects of atorvastatin and pravastatin on carotid artery intima-media thickness. 2001;141:342-7 (Trial design)
- Maruyama Y (see Kato et al). 2001;141:940-3
- Marwick TH (see Fathi and Marwick). 2001;141:694-703 (Prog. cardiol.)
- Massari F (see Pitzalis et al). 2001;141:765-71
- Mastropasqua F (see Pitzalis et al). 2001;141:765-71
- Mathias W (see Cortigiani et al). 2001;141:621-9
- Mattila K (see Ylitalo et al). 2001;141:e10
- Mautner B (see Santopinto et al). 2001;141:566-72
- Maximal Individual Therapy in Acute Myocardial Infarction (MITRA) Study Group (see Frilling et al). 2001;141:200-5
- Mayer C (see Clark et al). 2001;141:684-90
- Maynard C (see Kim et al). 2001;141:75-7
- Mazzoni V (see Cortigiani et al). 2001;141:621-9
- McCabe CH (see Giugliano et al). 2001;141:742-50
- McCabe CH (see Santopinto et al). 2001;141:566-72
- McCormick DJ (see Silva et al). 2001;141:353-9
- McDonagh TA (see Murdoch et al). 2001;141:800-7
- McGuire DK, O'Shea JC, Dyke CK, Velazquez EJ, Hudson MP. Highlights from the XXII Congress of the European Society of Cardiology: August 26 to 30, 2000. 2001;141:164-72 (Meetings)
- McGuire DK (see O'Shea et al). 2001;141:306-18 (Meetings)
- McMurray JIV (see Murdoch et al). 2001;141:800-7
- McNulty SE (see Shah et al). 2001;141:908-14
- McPherson R, Angus C, Murray P, Genest J Jr, WATCH Investigators. Efficacy of atorvastatin in achieving National Cholesterol Education Program low-density lipoprotein targets in women with severe dyslipidemia and cardiovascular disease or risk factors for cardiovascular disease: The Women's Atorvastatin Trial on Cholesterol (WATCH). 2001;141:949-56
- Mehran R, Dangas G, Abizaid A, Lansky AJ, Mintz GS, Pichard AD, Satler LF, Kent KM, Waksman R, Stone GW, Leon MB. Treatment of focal in-stent restenosis with balloon angioplasty alone versus stenting: Short- and long-term results. 2001;141:610-14
- Mele D, Schwammenthal E, Pedini I, Torp H, Nesta F, Vandervoort P, Alboni P, Levine RA. A semiautomated objective technique for applying the proximal isovelocity surface area method to quantitate mitral regurgitation: Clinical studies with the digital flow map. 2001;141:653-60
- Menapace F (see Aikawa et al). 2001;141:234-42
- Menozi A (see Modena et al). 2001;141:41-6
- Merz NB (see Reis et al). 2001;141:735-41
- Messano L (see Lanza et al). 2001;141:808-12
- Messerli FH (see Sharabi et al). 2001;141:1014-7
- Michaud GF (see Sticherling et al). 2001;141:813-16
- Miller DP (see Pilote et al). 2001;141:559-65

- Miller WL (see Clements and Miller). 2001;141:e5
Mintz GS (see Mehran et al). 2001;141:610-14
Mittal S (see Stein et al). 2001;141:282-8
Modena MG, Aveta P, Menozzi A, Rossi R. Aldosterone inhibition limits collagen synthesis and progressive left ventricular enlargement after anterior myocardial infarction. 2001;141:41-6
Al Mohammad A, Mahy IR, Buckley A, Cargill RI, Norton MY, Welch AE, Walton S. Does the presence of hibernating myocardium in patients with impaired left ventricular contraction affect QT dispersion? 2001;141:944-8
Molitero DJ (see Cho et al). 2001;141:599-602
Morady F (see Sticherling et al). 2001;141:813-16
Moraes RS (see Ribeiro et al). 2001;141:260-5
Mori N (see Ohba et al). 2001;141:751-8
Morino Y (see Kozuma et al). 2001;141:124-30
Moriyama Y (see Nishiyama et al). 2001;141:e9
Morrisey R (see Greenon et al). 2001;141:447-55
Morrisey R (see Maisel et al). 2001;141:367-74
Morrow DA (see de Lemos et al). 2001;141:592-8
Morton JJ (see Murdoch et al). 2001;141:800-7
Motro M (see Fisman et al). 2001;141:485-90
Murayama M (see Ohba et al). 2001;141:751-8
Murdoch DR, McDonagh TA, Farmer R, Morton JJ, McMurray JJV, Dargie HJ. ADEPT: Addition of the AT₁ receptor antagonist eprosartan to ACE inhibitor therapy in chronic heart failure trial: Hemodynamic and neurohormonal effects. 2001;141:800-7
Murphy SA (see de Lemos et al). 2001;141:592-8
Murray P (see McPherson et al). 2001;141:949-56
Musante FC (see Guazzi et al). 2001;141:139-47
Musha H (see Ohba et al). 2001;141:751-8
Muto H (see Yamazaki et al). 2001;141:645-52
Mwawasi G (see Kereiakes et al). 2001;141:348-52
Myocardial Infarction Registry (MIR) Study Group (see Frilling et al). 2001;141:200-5

N

- Nagashima J (see Ohba et al). 2001;141:751-8
Nageh T, de Belder AJ, Thomas MR, Williams IL, Wainwright RJ. A Randomised Trial of Endoluminal Reconstruction Comparing the NIR stEnt and the Wallstent in Angioplasty of Long Segment Coronary Disease: Results of the RENEWAL Study. 2001;141:971-6
Nakamura S (see Tsuka et al). 2001;141:615-20
Nanjo S (see Yamazaki et al). 2001;141:645-52
Nanthakumar K, Graham AT, Robinson TI, Grande P, Pugash RA, Clarke JA, Hutchison SJ, Mandzia JL, Hyland RH, Faughnan ME. Contrast echocardiography for detection of pulmonary arteriovenous malformations. 2001;141:243-6
Nastasić S (see Maras et al). 2001;141:e8
Natarajan MK (see Jong et al). 2001;141:218-25
National Registry of Myocardial Infarction 2 Investigators (see Barron et al). 2001;141:xxx9
Nešković AN (see Maras et al). 2001;141:e8
Negassa A (see Öunpuu et al). 2001;141:711-21 (Prog. cardiol.)
Nesta F (see Mele et al). 2001;141:653-60
Newman MF. Troponin I in cardiac surgery: Marking the future. 2001;141:325-6 (Editorial)
Nguyen-Ho P (see Krahn et al). 2001;141:111-16
Nichol P (see Spertus et al). 2001;141:550-8
Nicolosi GL (see Giannuzzi et al). 2001;141:131-8
Niemelä M (see Ylitalo et al). 2001;141:e10
Nieminen MS (see Palmieri et al). 2001;141:784-91
Nishi H (see Lee et al). 2001;141:184-9 (Prog. cardiol.)
Nishiyama K, Yasue H, Moriyama Y, Tsunoda R, Ogawa H, Yoshimura M, Kugiyama K. Acute effects of melatonin administration on cardiovascular autonomic regulation in healthy men. 2001;141:e9

- Nissen SE (see Ziada et al). 2001;141:823-31
Norton MY (see Mohammad et al). 2001;141:944-8
Noukas IG (see Karvounis et al). 2001;141:e7
Nozar J (see Papagiannis et al). 2001;141:491-9

O

- O'Connell AM, Crawford MH, Abrams J. Heart failure disease management in an indigent population. 2001;141:254-8
O'Connor CM (see Gattis et al). 2001;141:331-3 (Editorial)
O'Connor CM (see Shah et al). 2001;141:528-35 (Trial design), xxx6
Oetgen WJ (see Rathore et al). 2001;141:47-54
Ogawa H (see Nishiyama et al). 2001;141:e9
O'Grady MJ (see Ilcerc et al). 2001;141:992-8
Ohba H, Takada H, Musha H, Nagashima J, Mori N, Awaya T, Omiya K, Murayama M. Effects of prolonged strenuous exercise on plasma levels of atrial natriuretic peptide and brain natriuretic peptide in healthy men. 2001;141:751-8
Ohman EM, Hochman JS. Aortic counterpulsation in acute myocardial infarction: Physiologically important but does the patient benefit? 2001;141:889-92 (Editorial)
Ohme F (see Ortlepp et al). 2001;141:671-6
Okazaki R (see Tomiyama et al). 2001;141:422-7
Okin PM (see Vakili et al). 2001;141:334-41 (Prog. cardiol.)
Okuda J (see Kosuge et al). 2001;141:759-64
Okumura K (see Inokubo et al). 2001;141:211-17
Olarie A (see Kron et al). 2001;141:92-8
Oliveira E (see Ribeiro et al). 2001;141:260-5
O'Malley PG (see Hunt et al). 2001;141:206-10
O'Malley PG (see Markwood et al). 2001;141:342-7 (Trial design)
O'Malley PG (see Taylor et al). 2001;141:463-8
Omiya K (see Ohba et al). 2001;141:751-8
Oral H (see Sticherling et al). 2001;141:813-16
Orav EJ (see Tsevat et al). 2001;141:727-34
Ornato JP (see Kontos et al). 2001;141:360-6
O'Rourke RA. And the beat goes on. 2001;141:319-20 (Editorial)
Ortlepp JR, Breithardt O, Ohme F, Hanrath P, Hoffmann R. Lack of association among five genetic polymorphisms of the renin-angiotensin system and cardiac hypertrophy in patients with aortic stenosis. 2001;141:671-6
O'Shea JC, Bahit MC, Tolleson TR, Cabell C, Dyke CK, Kaul A, McGuire DK, East MA. Highlights from the American Heart Association Annual Scientific Sessions 2000: November 12 to 15, 2000. 2001;141:306-18 (Meetings)
O'Shea JC, Califf RM. International differences in cardiovascular clinical trials. 2001;141:866-74 (Meetings)
O'Shea JC, Califf RM. International differences in cardiovascular clinical trials—Introduction. 2001;141:864-5 (Meetings)
O'Shea JC, Califf RM. International differences in treatment effects in cardiovascular clinical trials. 2001;141:875-80 (Meetings)
O'Shea JC (see McGuire et al). 2001;141:164-72 (Meetings)
O'Shea JC (see Shibata et al). 2001;141:1019-24 (Meetings)
Otašević P (see Maras et al). 2001;141:e8
Oudiz RJ (see Khaleeli et al). 2001;141:637-44
Öunpuu S, Negassa A, Yusuf S. INTER-HEART Investigators. INTER-HEART: A global study of risk factors for acute myocardial infarction. 2001;141:711-21 (Prog. cardiol.)

P

- Pacchiana CM (see Cohen et al). 2001;141:391-401
Packer M, Antonopoulos GV, Berlin JA, Chittams J, Konstam MA, Udelsdon JE. Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: Results of a meta-analysis. 2001;141:899-907

- Packer M, Wittes J, Stump D. Terms of reference for Data and Safety Monitoring Committees. 2001;141:542-7 (Meetings)
- Pahlm O (see Ringborn et al). 2001;141:573-9
- Palmieri V, Wachtell K, Gerds E, Bella JN, Papademetriou V, Tuxen C, Nieminen MS, Dahlöf B, de Simone G, Devereux RB. Left ventricular function and hemodynamic features of inappropriate left ventricular hypertrophy in patients with systemic hypertension: The LIFE Study. 2001;141:784-91
- Palosuo T (see Kervinen et al). 2001;141:580-5
- Paolasso E (see Cohen et al). 2001;141:391-401
- Papademetriou V (see Palmieri et al). 2001;141:784-91
- Papagiannis J, Van Praagh R, Schwint O, D'Orsogna L, Qureshi F, Reynolds J, Kallfelz C, Nozar J. Congenital left ventricular aneurysm: Clinical, imaging, pathologic, and surgical findings in seven new cases. 2001;141:491-9
- Paranicas M (see Devereux et al). 2001;141:439-46
- Paranicas M (see Ilıcil et al). 2001;141:992-8
- Parharidis GE (see Karvounis et al). 2001;141:e7
- Park J-E (see Lee et al). 2001;141:184-9 (Prog. cardiol.)
- Park S-J (see Hong et al). 2001;141:832-6
- Park S-W (see Hong et al). 2001;141:832-6
- Park SW (see Lee et al). 2001;141:184-9 (Prog. cardiol.)
- Parrillo JE (see Sgarbossa et al). 2001;141:507-17 (Curriculum cardiol.)
- Parsons LS (see Barron et al). 2001;141:933-9
- Patacsil P (see Baruch et al). 2001;141:e6
- Patel AR (see Kuvin et al). 2001;141:327-8 (Editorial)
- Pauwels EKJ (see Bavelaar-Croon et al). 2001;141:383-90
- P²C² HIV Study Group (see Lai et al). 2001;141:661-70
- Pedini I (see Mele et al). 2001;141:653-60
- Pelosi F (see Sticherling et al). 2001;141:813-16
- Pepine CJ (see Reis et al). 2001;141:735-41
- Perez de Arenaza D (see Shibata et al). 2001;141:1019-24 (Meetings)
- Peters SR (see Khaleeli et al). 2001;141:637-44
- Peterson GE (see Cabell and Peterson). 2001;141:6-8 (Editorial)
- Pettersson J (see Ringborn et al). 2001;141:573-9
- Peuhkurinen K (see Ylitalo et al). 2001;141:e10
- Pfau SE (see Clark et al). 2001;141:684-90
- Pfeffer MA (see Aikawa et al). 2001;141:234-42
- Phoon CKL. Estimation of pressure gradients by auscultation: An innovative and accurate physical examination technique. 2001;141:500-6
- Piazza R (see Giannuzzi et al). 2001;141:131-8
- Picano E (see Cortigiani et al). 2001;141:621-9
- Pichard AD (see Mehran et al). 2001;141:610-14
- Pieper KS (see Labinaz et al). 2001;141:469-77
- Piérard LA (see Lancellotti et al). 2001;141:772-9
- Pilote L, Miller DP, Califf RM, Topol EJ. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO-I) Investigators. Recurrent ischemia after thrombolysis for acute myocardial infarction. 2001;141:559-65
- Pilote L (see Eisenberg et al). 2001;141:837-46
- Pina I (see Baruch et al). 2001;141:e6
- Pinski SL (see Exner et al). 2001;141:99-104
- Pittman D (see Raggi et al). 2001;141:722-6 (Trial design)
- Pitzalis MV, Iacoviello M, Todarello O, Fioretti A, Guida P, Massari F, Mastropasqua F, Dello Russo G, Rizzon P. Depression but not anxiety influences the autonomic control of heart rate after myocardial infarction. 2001;141:765-71
- Plehn J (see Aikawa et al). 2001;141:234-42
- Pocock S, Furburg CD. Procedures of Data and Safety Monitoring Committees. 2001;141:289-94 (Meetings)
- Pomerantz PMA (see Mansur et al). 2001;141:78-86
- Ponte CI (see Cohen et al). 2001;141:391-401
- Popma JJ (see Silva et al). 2001;141:353-9
- Popović AD (see Maršić et al). 2001;141:e8
- Popović Z (see Maršić et al). 2001;141:e8
- Porway M (see Webb et al). 2001;141:964-70
- Powers ER (see Ragosta et al). 2001;141:456-62
- Prevot S (see Cottin et al). 2001;141:999-1006
- PRICE Investigators. Comparative 30-day economic and clinical outcomes of platelet glycoprotein IIb/IIIa inhibitor use during elective percutaneous coronary intervention: Prairie ReoPro Versus Integrilin Cost Evaluation (PRICE) Trial. 2001;141:402-9
- PRINCE Investigators (see Albert et al). 2001;141:893-8 (Trial design)
- Pugash RA (see Nanthakumar et al). 2001;141:243-6

Q

- Qureshi F (see Papagiannis et al). 2001;141:491-9

R

- Radford MJ (see Chen et al). 2001;141:410-17
- Raggi P, Callister TQ, Davidson M, Welty FK, Bachmann GA, Laskey R, Pittman D, Kafonek S, Scott R. Aggressive versus moderate lipid-lowering therapy in postmenopausal women with hypercholesterolemia: Rationale and design of the Beyond Endorsed Lipid Lowering with EBT Scanning (BELLES) trial. 2001;141:722-6 (Trial design)
- Raggi P, Cooil B, Callister TQ. Use of electron beam tomography data to develop models for prediction of hard coronary events. 2001;141:375-82
- Ragosta M, Powers ER, Samady H, Gimple LW, Sarembock JJ, Beller GA. Relationship between extent of residual myocardial viability and coronary flow reserve in patients with recent myocardial infarction. 2001;141:456-62
- Raitt M (see Kron et al). 2001;141:92-8
- Ramahi TM (see Clark et al). 2001;141:684-90
- Ramee SR (see Silva et al). 2001;141:353-9
- Rathore SS, Gersh BJ, Berger PB, Weinfurt KP, Oetgen WJ, Schulman KA, Solomon AJ. Acute myocardial infarction complicated by heart block in the elderly: Prevalence and outcomes. 2001;141:47-54
- Rauchhaus M (see Doehner et al). 2001;141:792-9
- Raymond RJ, Dehmer GJ, Theoharides TC, Deliangryis EN. Elevated interleukin-6 levels in patients with asymptomatic left ventricular systolic dysfunction. 2001;141:435-8
- Reichek N (see Reis et al). 2001;141:735-41
- Reicher-Reiss H (see Shostan et al). 2001;141:478-84
- Reis SE, Holubkov R, Smith AJC, Kelsey SF, Sharaf BL, Reichek N, Rogers WJ, Merz NB, Sopko G, Pepine CJ, WISE Investigators. Coronary microvascular dysfunction is highly prevalent in women with chest pain in the absence of coronary artery disease: Results from the NHLBI WISE study. 2001;141:735-41
- Renfro EG (see Kron et al). 2001;141:92-8
- Ressencourt O (see Cottin et al). 2001;141:999-1006
- Reveal Investigators (see Krahn et al). 2001;141:817-21
- Reynolds J (see Papagiannis et al). 2001;141:491-9
- Rezaizadeh K (see Cottin et al). 2001;141:999-1006
- Rhee K-S (see Hong et al). 2001;141:832-6
- Rhoades ER (see Devereux et al). 2001;141:439-46
- Ribeiro ALP, Moraes RS, Ribeiro JP, Ferlin EL, Torres RM, Oliveira E, Rocha MOC. Parasympathetic dysautonomia precedes left ventricular systolic dysfunction in Chagas disease. 2001;141:260-5
- Ribeiro JP (see Ribeiro et al). 2001;141:260-5
- Ricci E (see Lanza et al). 2001;141:808-12
- Ridker PM (see Albert et al). 2001;141:893-8 (Trial design)
- Rihal CS (see Wilson et al). 2001;141:704-10 (Prog. cardiol.)
- Ringborn M, Pahlm O, Wagner GS, Warren SG, Pettersson J. The absence of high-frequency QRS changes in the presence of standard electrocardiographic QRS changes of old myocardial infarction. 2001;141:573-9

- Rizo-Patron C (see Kron et al). 2001;141:92-8
Rizza RA (see Hasdai et al). 2001;141:117-23
Rizzon P (see Pitzalis et al). 2001;141:765-71
Robbins D (see Devereux et al). 2001;141:439-46
Robbins DC (see Iltercil et al). 2001;141:992-8
Robinson TI (see Nanthakumar et al). 2001;141:243-6
Rocha MOC (see Ribeiro et al). 2001;141:260-5
Rodas MA (see Cohen et al). 2001;141:391-401
Rodeheffer RJ (see Devereux et al). 2001;141:439-46
Rogers WJ (see Reis et al). 2001;141:735-41
Rohde L (see Aikawa et al). 2001;141:234-42
Rollins SA (see Clark et al). 2001;141:684-90
Roman MJ (see Devereux et al). 2001;141:439-46
Roman MJ (see Iltercil et al). 2001;141:992-8
ROSETTA Investigators (see Eisenberg et al). 2001;141:837-46
Ross AM (see Birnbaum et al). 2001;141:915-24
Rossi R (see Modena et al). 2001;141:41-6
Rott D, Behar S, Hod H, Feinberg MS, Boyko V, Mandelzweig L, Kaplinsky E, Gottlieb S, Argatoban in Acute Myocardial Infarction-2 (ARGAMI-2) Study Group. Improved survival of patients with acute myocardial infarction with significant left ventricular dysfunction undergoing invasive coronary procedures. 2001;141:267-76
Rouleau J-L (see Aikawa et al). 2001;141:234-42
Rychik J (see Fogel et al). 2001;141:630-6

S

- Sacks FM (see Tsevat et al). 2001;141:727-34
Sakata K (see Kachi et al). 2001;141:55-64
Samady H (see Ragosta et al). 2001;141:456-62
Sanborn TA (see Webb et al). 2001;141:964-70
Santini C (see Lanza et al). 2001;141:808-12
Santopinto J, Gurfinkel EP, Torres V, Marcos E, Bozovich GE, Mautner B, McCabe CH, Antman EM. Prior aspirin users with acute non-ST-elevation coronary syndromes are at increased risk of cardiac events and benefit from enoxaparin. 2001; 141:566-72
Santorelli FM, Tessa A, d'Amati G, Casalic C. The emerging concept of mitochondrial cardiomyopathies. 2001;141:e1 (Prog. cardi.)
Santoro GM, Bolognese L. Coronary stenting and platelet glycoprotein IIb/IIIa receptor blockade in acute myocardial infarction. 2001;141:S26-35
Sapirstein JS, Smith PK. The "ideal" replacement heart valve. 2001;141:856-60 (Meetings)
Sapirstein W. Designing trials for testing prosthetic cardiac valves: A Food and Drug Administration perspective. 2001; 141:861-3 (Meetings)
Sarembok IJ (see Ragosta et al). 2001;141:456-62
Sasaki K (see Kachi et al). 2001;141:55-64
Satler LF (see Mehran et al). 2001;141:610-14
Sato M (see Lee et al). 2001;141:184-9 (Prog. cardi.)
Schaaf CH (see Kim et al). 2001;141:73-7
Schechter D (see Eisenberg et al). 2001;141:837-46
Scheiner M (see Stein et al). 2001;141:282-8
Schiele R (see Frilling et al). 2001;141:200-5
Schmidt KL (see Kontos et al). 2001;141:360-6
Schneider S (see Frilling et al). 2001;141:200-5
Schreiner MS, Greeley WJ. Safe and effective for children? 2001; 141:3-5 (Editorial)
Schuhwerk KC (see de Lemos et al). 2001;141:592-8
Schulman KA (see Rathore et al). 2001;141:47-54
Schulz-Menger J (see Wassmuth et al). 2001;141:1007-13
Schwammenthal E (see Mele et al). 2001;141:653-60
Schweiger M (see de Lemos et al). 2001;141:592-8
Schwint O (see Papagiannis et al). 2001;141:491-9
Scott CG (see Hasdai et al). 2001;141:117-23

- Scott R (see Raggi et al). 2001;141:722-6 (Trial design)
Secondary Prevention Reinfarction Israeli Nifedipine Trial (SPRINT) Study Group (see Shotan et al). 2001;141:478-84
Sedlis S (see Eisenberg et al). 2001;141:837-46
Seidel L (see Lancellotti et al). 2001;141:772-9
Senges J (see Frilling et al). 2001;141:200-5
Setaro JF (see Clark et al). 2001;141:684-90
Setum CM (see Silva et al). 2001;141:353-9
Sgarbossa EB, Birnbaum Y, Parrillo JE. Electrocardiographic diagnosis of acute myocardial infarction: Current concepts for the clinician. 2001;141:507-17 (Curriculum cardi.)
Shah MR, O'Connor CM, Sopko G, Hasselblad V, Califf RM, Stevenson LW, ESCAPE Investigators. Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE): Design and rationale. 2001;141:528-35 (Trial design)
Shah MR, Stinnett SS, McNulty SE, Gheorghiadu M, Zannad F, Uretsky B, Adams KF Jr, Califf RM, O'Connor CM. Hemodynamics as surrogate end points for survival in advanced heart failure: An analysis from FIRST. 2001;141:xxx6
Shammash JB, Trost JC, Gold JM, Berlin JA, Golden MA, Kimmel SE. Perioperative β -blocker withdrawal and mortality in vascular surgical patients. 2001;141:148-53
Sharabi Y, Almer Z, Hanin A, Messerli FH, Ben-Cnaan R, Grossman E. Reproducibility of exaggerated blood pressure response to exercise in healthy patients. 2001;141:xx21
Sharaf BL (see Reis et al). 2001;141:735-41
Sharma R (see Doehner et al). 2001;141:792-9
Sheiban I, Fragasso G, Lu C, Tonni S, Trevi GP, Chierchia SL. Influence of treatment delay on long-term left ventricular function in patients with acute myocardial infarction successfully treated with primary angioplasty. 2001;141:603-9
Sheldon RS (see Exner et al). 2001;141:99-104
Shibata MC, Flather MD, Perez de Arenaza D, Wang D, O'Shea JC. Potential impact of socioeconomic differences on clinical outcomes in international clinical trials. 2001;141:1019-24 (Meetings)
Shimizu M (see Kosuge et al). 2001;141:759-64
Shimshak TM (see Kereiakes et al). 2001;141:348-52
SHOCK Investigators (see Webb et al). 2001;141:964-70
Shotan A, Gottlieb S, Goldbourt U, Boyko V, Reicher-Reiss H, Arad M, Mandelzweig L, Hod H, Kaplinsky E, Behar S, Secondary Prevention Reinfarction Israeli Nifedipine Trial (SPRINT) Study Group, Israel Thrombolytic Survey Group. Prognosis of patients with a recurrent acute myocardial infarction before and in the reperfusion era—A national study. 2001;141:478-84
Sigmon KN (see Madan et al). 2001;141:226-33
Silva JA, Ramee SR, Cohen DJ, Carrozza JP, Popma JJ, Lansky AA, Dandreo K, Baim DS, George BS, McCormick DJ, Setum CM, Kuntz RE. Rheolytic thrombectomy during percutaneous revascularization for acute myocardial infarction: Experience with the Angiojet catheter. 2001;141:353-9
Silva Oropeza E (see Cohen et al). 2001;141:391-401
Simonsen S (see Gullestad et al). 2001;141:418-21
Sitafidis G (see Hahalis et al). 2001;141:428-34
Sjölin M (see Karlson et al). 2001;141:977-84
Skane AC (see Krahm et al). 2001;141:111-16, 817-21
Sketch MH Jr (see Labimaz et al). 2001;141:469-77
Slater JN (see Webb et al). 2001;141:964-70
Sleeper LA (see Webb et al). 2001;141:964-70
Slotwiner DJ (see Stein et al). 2001;141:282-8
Smilovitch M (see Eisenberg et al). 2001;141:837-46
Smit AC (see Madan et al). 2001;141:226-33
Smith AJC (see Reis et al). 2001;141:735-41
Smith PK (see Sapirstein and Smith). 2001;141:856-60 (Meetings)
Solal AC (see Logeart et al). 2001;141:247-53
Solomon AJ (see Rathore et al). 2001;141:47-54
Solomon SD (see Aikawa et al). 2001;141:234-42
Song J-K (see Hong et al). 2001;141:832-6

- Song J-M (see Hong et al). 2001;141:832-6
 Sopko G (see Reis et al). 2001;141:735-41
 Sopko G (see Shah et al). 2001;141:528-35 (Trial design)
 Spertus JA, Dewhurst T, Dougherty CM, Nichol P. Testing the effectiveness of converting patients to long-acting antianginal medications: The Quality of Life in Angina Research Trial (QUART). 2001;141:550-8
 Stafford RS (see Wang et al). 2001;141:957-63
 Staggers J (see Albert et al). 2001;141:893-8 (Trial design)
 Starc TJ (see Lai et al). 2001;141:661-70
 Stebbins AL (see Labinaz et al). 2001;141:469-77
 Stein KM, Slotwimer DJ, Mittal S, Scheiner M, Markowitz SM, Lerman BB. Formal analysis of the optimal duration of tilt testing for the diagnosis of neurally mediated syncope. 2001;141:282-8
 Stevenson LW (see Shah et al). 2001;141:528-35 (Trial design)
 Stewart MJ (see Sutton et al). 2001;141:677-83
 Sticherling C, Chough SP, Baker RL, Wasmer K, Oral H, Tada H, Horwood L, Kim MH, Pelosi F, Michaud GF, Strickberger SA, Morady F, Knight BP. Prevalence of central venous occlusion in patients with chronic defibrillator leads. 2001;141:813-16
 Stinnett SS (see Shah et al). 2001;141:908-14
 Stoian I (see Giannuzzi et al). 2001;141:131-8
 Stone GW (see DeGeare et al). 2001;141:15-24 (Curriculum cardiol.)
 Stone GW (see Mehran et al). 2001;141:610-14
 Strasberg B (see Birnbaum et al). 2001;141:915-24
 Strauss BH (see Jong et al). 2001;141:218-25
 Strickberger SA (see Sticherling et al). 2001;141:813-16
 Stump D (see Packer et al). 2001;141:542-7 (Meetings)
 Stump DC (see Wang-Clow et al). 2001;141:33-40
 Sugiura T (see Tsuka et al). 2001;141:615-20
 Sumner AE (see Tulenko et al). 2001;141:S1-11
 Suskin N (see Krahn et al). 2001;141:111-16
 Sutton AGC, Finn P, Grech ED, Hall JA, Stewart MJ, Davies A, de Belder MA. Early and late reactions after the use of iopamidol 340, ioxaglate 320, and iodixanol 320 in cardiac catheterization. 2001;141:677-83
- T**
- Tada H (see Sticherling et al). 2001;141:813-16
 Takada H (see Ohba et al). 2001;141:751-8
 Takaoka H (see Kawai et al). 2001;141:925-32
 Talley JD (see Webb et al). 2001;141:964-70
 Tamura T (see Kozuma et al). 2001;141:124-30
 Tanabe K (see Kozuma et al). 2001;141:124-30
 Tanaka S (see Kato et al). 2001;141:940-3
 Tatum JL (see Kontos et al). 2001;141:360-6
 Tavazzi L (see Giannuzzi et al). 2001;141:131-8
 Taylor AJ, Feuerstein I, Wong H, Barko W, Brazaitis M, O'Malley PG. Do conventional risk factors predict subclinical coronary artery disease? Results from the Prospective Army Coronary Calcium Project. 2001;141:463-8
 Taylor AJ (see Hunt et al). 2001;141:206-10
 Taylor AJ (see Markwood et al). 2001;141:342-7 (Trial design)
 Tchong JE (see Madan et al). 2001;141:226-33
 Tedgui A (see Kennedy et al). 2001;141:e4 (Letter)
 Temporelli PL (see Giannuzzi et al). 2001;141:131-8
 Tenenbaum A (see Fisman et al). 2001;141:485-90
 Tenkanen L (see Kervinen et al). 2001;141:580-5
 Tessa A (see Santorelli et al). 2001;141:e1 (Prog. cardiol.)
 Theoharides TC (see Raymond et al). 2001;141:435-8
 Thomas MR (see Nageh et al). 2001;141:971-6
 Thompson CA (see Goldberg et al). 2001;141:65-72
 Thrombolysis in Myocardial Infarction (TIMI) Investigators (see Giugliano et al). 2001;141:742-50
 TIMI 14 Investigators (see de Lemos et al). 2001;141:592-8
 Tochikubo O (see Kosuge et al). 2001;141:759-64
 Todarello O (see Pitzalis et al). 2001;141:765-71
 Tokmakova M (see Logeart et al). 2001;141:247-53
 Tolleson TR (see O'Shea et al). 2001;141:306-18 (Meetings)
 Tomiyama H, Watanabe G, Abe M, Okazaki R, Yoshida H, Doba N. Systemic and renal effects of atrial natriuretic peptide in patients with heart failure treated with angiotensin-converting enzyme inhibitor or in acute saline solution loading. 2001;141:422-7
 Tonni S (see Sheiban et al). 2001;141:603-9
 Topol EJ (see Cho et al). 2001;141:599-602
 Topol EJ (see Cohen et al). 2001;141:391-401
 Topol EJ (see Labinaz et al). 2001;141:469-77
 Topol EJ (see Pilote et al). 2001;141:559-65
 Torp H (see Mele et al). 2001;141:653-60
 Torres RM (see Ribeiro et al). 2001;141:260-5
 Torres V (see Santopinto et al). 2001;141:566-72
 Tousoulis D, Homaei H, Ahmed N, Asimakopoulos G, Zouridakis E, Toutouzas P, Davies GJ. Increased plasma adhesion molecule levels in patients with heart failure who have ischemic heart disease and dilated cardiomyopathy. 2001;141:277-80
 Toutouzas P (see Tousoulis et al). 2001;141:277-80
 Touzery C (see Cottin et al). 2001;141:999-1006
 Toyama J (see Lee et al). 2001;141:184-9 (Prog. cardiol.)
 Trevi GP (see Sheiban et al). 2001;141:603-9
 Trost JC (see Shammash et al). 2001;141:148-53
 Tsevat J, Kuntz KM, Orav EJ, Weinstein MC, Sacks FM, Goldman L. Cost-effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels. 2001;141:727-34
 Tsuka Y, Sugiura T, Hatada K, Nakamura S, Yuasa F, Iwasaka T. Clinical significance of ST-segment elevation in lead V1 in patients with acute inferior wall Q-wave myocardial infarction. 2001;141:615-20
 Tsunoda R (see Nishiyama et al). 2001;141:e9
 Tulenko TN, Sumner AE, Chen M, Huang Y, Laury-Kleintop L, Ferdinand FD. The smooth muscle cell membrane during atherogenesis: A potential target for amlodipine in atheroprotection. 2001;141:S1-11
 Turpie AGG (see Becker et al). 2001;141:1025-37 (Meetings)
 Tuxen C (see Palmieri et al). 2001;141:784-91
 Tuzcu EM (see Ziada et al). 2001;141:823-31
- U**
- Udelson JE (see Packer et al). 2001;141:899-907
 Ueland T (see Gullestad et al). 2001;141:418-21
 Umemura S (see Kosuge et al). 2001;141:759-64
 Uretsky B (see Shah et al). 2001;141:908-14
 Urrutia CE (see Cohen et al). 2001;141:391-401
- V**
- Vaara O (see Kervinen et al). 2001;141:580-5
 Vagenakis AG (see Hahalis et al). 2001;141:428-34
 Vakili BA, Okin PM, Devereux RB. Prognostic implications of left ventricular hypertrophy. 2001;141:334-41 (Prog. cardiol.)
 Valkama J (see Ylitalo et al). 2001;141:e10
 Van Boven AJ (see Amoroso et al). 2001;141:S22-5
 Van de Werf F (see de Lemos et al). 2001;141:592-8
 Van de Werf F (see Giugliano et al). 2001;141:742-50
 Van de Werf F (see Wang-Clow et al). 2001;141:33-40
 van der Wall EE (see Bavelaar-Croon et al). 2001;141:383-90
 Van Praagh R (see Papagiannis et al). 2001;141:491-9
 VanBenthuyzen K (see Bar-Or et al). 2001;141:985-91
 Vandervoort P (see Mele et al). 2001;141:653-60

- Velazquez EJ (see McGuire et al). 2001;141:164-72 (Meetings)
Vernalis MN (see Hunt et al). 2001;141:206-10
Vigliano CA (see Laguens et al). 2001;141:780-3
Virmani R (see Burke et al). 2001;141:558-62
Vuk L (see Maras et al). 2001;141:e8

W

- Wachtell K (see Palmieri et al). 2001;141:784-91
Wagner GS (see Birnbaum et al). 2001;141:915-24
Wagner GS (see Ringborn et al). 2001;141:573-9
Wainwright RJ (see Nageh et al). 2001;141:971-6
Waksman R (see Mehran et al). 2001;141:610-14
Walton S (see Mohammad et al). 2001;141:944-8
Wang-Clow F, Fox NL, Cannon CP, Gibson CM, Berlioli S, Bluhmki E, Danays T, Braunwald E, Van de Werf F, Stump DC. Determination of a weight-adjusted dose of TNK-tissue plasminogen activator. 2001;141:33-40
Wang D (see Shibata et al). 2001;141:1019-24 (Meetings)
Wang TJ, Stafford RS, Ausiello JC, Chaisson CE. Randomized clinical trials and recent patterns in the use of statins. 2001;141:957-63
Wang Y (see Chen et al). 2001;141:410-17
Warren SG (see Ringborn et al). 2001;141:573-9
Wasnier K (see Sticherling et al). 2001;141:813-16
Wassef M (see Kennedy et al). 2001;141:e4 (Letter)
Wassmuth R, Lentzsch S, Erdbrugger U, Schulz-Menger J, Doerken B, Dietz R, Friedrich MG. Subclinical cardiotoxic effects of anthracyclines as assessed by magnetic resonance imaging—A pilot study. 2001;141:1007-14
Watanabe G (see Tomiyama et al). 2001;141:422-7
Watanuki A (see Kachi et al). 2001;141:55-64
WATCH Investigators (see McPherson et al). 2001;141:949-56
Waters DD (see Azar and Waters). 2001;141:881-3 (Editorial)
Wathen M (see Kron et al). 2001;141:92-8
Weaver WD, Greenberg S. Making changes in clinical trials. 2001;141:295-300 (Meetings)
Webb JG, Sanborn TA, Sleeper LA, Carere RG, Buller CE, Slater JN, Baran KW, Koller PT, Talley JD, Porway M, Hochman JS, SHOCK Investigators. Percutaneous coronary intervention for cardiogenic shock in the SHOCK Trial Registry. 2001;141:964-70
Weinberg PM (see Fogel et al). 2001;141:630-6
Weinfurt KP (see Rathore et al). 2001;141:47-54
Weinstein MC (see Tsevat et al). 2001;141:727-34
Welch AE (see Mohammad et al). 2001;141:944-8
Welty FK (see Raggi et al). 2001;141:722-6 (Trial design)
Welty TK (see Devereux et al). 2001;141:439-46
Welty TK (see Iltercil et al). 2001;141:992-8
White HD (see Amos et al). 2001;141:586-91
Whitlock RML (see Amos et al). 2001;141:586-91
Whitlow PL (see Ziada et al). 2001;141:823-31
Wilcox RG (see Giugliano et al). 2001;141:742-50
Wilkoff B (see Kron et al). 2001;141:92-8
Williams BF (see Amos et al). 2001;141:586-91

- Williams IL (see Nageh et al). 2001;141:971-6
Wilson SH, Bell MR, Rihal CS, Bailey KR, Holmes DR Jr, Berger PB. Infarct artery reocclusion after primary angioplasty, stent placement, and thrombolytic therapy for acute myocardial infarction. 2001;141:704-10 (Prog. cardiol.)
Winkler JV (see Bar-Or et al). 2001;141:915-24
WISE Investigators (see Reis et al). 2001;141:735-41
Wittes J (see Packer et al). 2001;141:542-7 (Meetings)
Wolf JE (see Cottin et al). 2001;141:999-1006
Wolski K (see Cho et al). 2001;141:599-602
Wong H (see Taylor et al). 2001;141:463-8
Wood D, Joint European Societies Task Force. Established and emerging cardiovascular risk factors. 2001;141:S49-57

Y

- Yamasaki M (see Kozuma et al). 2001;141:124-30
Yamashina S (see Yamazaki et al). 2001;141:645-52
Yamazaki J, Muto H, Kabano T, Yamashina S, Nanjo S, Inoue A. Evaluation of β -blocker therapy in patients with dilated cardiomyopathy—Clinical meaning of iodine 123-metaiodobenzylguanidine myocardial single-photon emission computed tomography. 2001;141:645-52
Yao Q (see Kron et al). 2001;141:92-8
Yasue H (see Nishiyama et al). 2001;141:e9
Yee R (see Krahn et al). 2001;141:111-16, 817-21
Ylitalo K, Niemela M, Linnaluoto M, Valkama J, Mattila K, Peuhkurinen K. Evidence suggesting coronary vasodilation as the principal mechanism in the warm-up phenomenon. 2001;141:e10
Yokoyama M (see Kawai et al). 2001;141:925-32
Yoshida H (see Tomiyama et al). 2001;141:422-7
Yoshimoto N (see Kato et al). 2001;141:940-3
Yoshimura M (see Nishiyama et al). 2001;141:e9
Yoshino H (see Kachi et al). 2001;141:55-64
Yuasa F (see Tsuka et al). 2001;141:615-20
Yunus F (see Kamath et al). 2001;141:e3 (Letter)
Yusuf S (see DeMets and Yusuf). 2001;141:548-9 (Meetings)
Yusuf S (see Öunpuu et al). 2001;141:711-21 (Prog. cardiol.)

Z

- Zaglavara TA (see Karvounis et al). 2001;141:e7
Zahn R (see Frilling et al). 2001;141:200-5
Zannad F (see Shah et al). 2001;141:908-14
Zeller M (see Cottin et al). 2001;141:999-1006
Ziada KM, Kapadia SR, Belli G, Houghtaling PL, De Franco AC, Ellis SG, Whitlow PL, Franco I, Nissen SE, Tuzcu EM. Prognostic value of absolute versus relative measures of the procedural result after successful coronary stenting: Importance of vessel size in predicting long-term freedom from target vessel revascularization. 2001;141:823-31
Zoumbos NC (see Hahalis et al). 2001;141:428-34
Zouridakis E (see Tousoulis et al). 2001;141:277-80

Subject index*

A

Abciximab

- Abciximab and early adjunctive percutaneous coronary intervention are associated with improved ST-segment resolution after thrombolysis: Observations from the TIMI 14 Trial (de Lemos et al). 2001;141:592-8
- Bleeding risks with abciximab after full-dose thrombolysis in rescue or urgent angioplasty for acute myocardial infarction (Jong et al). 2001;141:218-25
- Dalteparin in combination with abciximab during percutaneous coronary intervention (Kereiakes et al). 2001;141:348-52
- Effect of smoking status and abciximab use on outcome after percutaneous coronary revascularization: Pooled analysis from EPIC, EPILOG, and EPISTENT (Cho et al). 2001;141:599-602

Acute coronary syndromes; see Angina pectoris; Myocardial infarction

ADEPT

- ADEPT: Addition of the AT₁ receptor antagonist eprosartan to ACE inhibitor therapy in chronic heart failure trial: Hemodynamic and neurohormonal effects (Murdoch et al). 2001;141:800-7

Adrenergic beta-antagonists

- Evaluation of β -blocker therapy in patients with dilated cardiomyopathy—Clinical meaning of iodine 123-metaiodobenzylguanidine myocardial single-photon emission computed tomography (Yamazaki et al). 2001;141:645-52
- Perioperative β -blocker withdrawal and mortality in vascular surgical patients (Shammash et al). 2001;141:148-53
- Plasma brain natriuretic peptide as a novel therapeutic indicator in idiopathic dilated cardiomyopathy during β -blocker therapy: A potential of hormone-guided treatment (Kawai et al). 2001;141:925-32
- Which β -blocker for heart failure? (Adams). 2001;141:884-8 (Editorial)

Aged

- Acute myocardial infarction complicated by heart block in the elderly: Prevalence and outcomes (Rathore et al). 2001;141:47-54
- Angiotensin-converting enzyme inhibitor dosages in elderly patients with heart failure (Chen et al). 2001;141:410-17
- A population-based assessment of left ventricular systolic dysfunction in middle-aged and older adults: The Strong Heart Study (Devereux et al). 2001;141:439-46

Albumin

- Reduced albumin-cobalt binding with transient myocardial ischemia after elective percutaneous transluminal coronary angioplasty: A preliminary comparison to creatine kinase-MB, myoglobin, and troponin I (Bar-Or et al). 2001;141:xx17

Aldosterone antagonists

- Aldosterone inhibition and heart failure: Too good to be true? (Francis). 2001;141:1-2 (Editorial)
- Aldosterone inhibition limits collagen synthesis and progressive left ventricular enlargement after anterior myocardial infarction (Modena et al). 2001;141:41-6

American Heart Association

- Highlights from the American Heart Association Annual Scientific Sessions 2000: November 12 to 15, 2000 (O'Shea et al). 2001;141:306-18 (Meetings)

*January, pp. 1-172; February, pp. 173-318, S1-62; March, pp. 319-506; April, pp. 507-690; May, pp. 691-880; June, pp. 881-1074.

Amiodarone

- Amiodarone is safe and highly effective therapy for supraventricular tachycardia in infants (Etheridge et al). 2001;141:105-10
- Single-day loading dose of oral amiodarone for the prevention of new-onset atrial fibrillation after coronary artery bypass surgery (Maraš et al). 2001;141:e8

Amlodipine

- The smooth muscle cell membrane during atherogenesis: A potential target for amlodipine in atheroprotection (Tulenko et al). 2001;141:S1-11

Aneurysm

- Congenital left ventricular aneurysm: Clinical, imaging, pathologic, and surgical findings in seven new cases (Papagiannis et al). 2001;141:491-9

Angina, unstable

- Anti-human skeletal muscle glycolipid antibodies in unstable angina (Laguens et al). 2001;141:780-3
- Early and late mortality after surgery for unstable angina in relation to Braunwald class (Bjessmo et al). 2001;141:9-14 (Curriculum cardiol.)
- Unstable angina in the Myocardial Infarction Triage and Intervention Registry (MITI): Short- and long-term outcomes in men and women (Kim et al). 2001;141:73-7
- Updated pathophysiologic concepts in unstable coronary artery disease (Conti). 2001;141:S12-14

Angina pectoris

- Direct thrombin inhibitors in acute coronary syndromes and during percutaneous coronary intervention: Design of a meta-analysis based on individual patient data (Direct Thrombin Inhibitor Trialists' Collaborative Group). 2001;141:e2 (Trial design)
- Joint effects of C-reactive protein and other risk factors on acute coronary events (Kervinen et al). 2001;141:580-5
- Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome (Inokubo et al). 2001;141:211-17
- Rationale and design of the GRACE (Global Registry of Acute Coronary Events) Project: A multinational registry of patients hospitalized with acute coronary syndromes (GRACE Investigators). 2001;141:190-9 (Trial design)
- Testing the effectiveness of converting patients to long-acting antianginal medications: The Quality of Life in Angina Research Trial (QUART) (Spertus et al). 2001;141:550-8
- Variation in patient management and outcomes for acute coronary syndromes in Latin America and North America: Results from the Platelet IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial (Cohen et al). 2001;141:391-401

Angiography

- Six-month angiographic follow-up after intravascular ultrasound-guided stenting of infarct-related artery: Comparison with non-infarct-related artery (Hong et al). 2001;141:832-6

AngioJet catheter

- Rheolytic thrombectomy during percutaneous revascularization for acute myocardial infarction: Experience with the AngioJet catheter (Silva et al). 2001;141:353-9

Angioplasty, transluminal, percutaneous coronary

- Bleeding risks with abciximab after full-dose thrombolysis in rescue or urgent angioplasty for acute myocardial infarction (Jong et al). 2001;141:218-25
- Drug therapy or coronary angioplasty for the treatment of coronary artery disease: New insights (Amoroso et al). 2001;141:S22-5
- Infarct artery reocclusion after primary angioplasty, stent placement, and thrombolytic therapy for acute myocardial infarction (Wilson et al). 2001;141:704-10 (Prog. cardiol.)
- Influence of treatment delay on long-term left ventricular

- function in patients with acute myocardial infarction successfully treated with primary angioplasty (Sheiban et al). 2001;141:603-9
- Interventional procedures in acute myocardial infarction (DeGeare et al). 2001;141:15-24 (Curriculum cardi.)
- Nicorandil, a potent cardioprotective agent, reduces QT dispersion during coronary angioplasty (Kato et al). 2001;141:940-3
- A Randomised Trial of Endoluminal Reconstruction Comparing the NIR stEnt and the Wallstent in Angioplasty of Long Segment Coronary Disease: Results of the RENEWAL Study (Nageh et al). 2001;141:971-6
- Reduced albumin-cobalt binding with transient myocardial ischemia after elective percutaneous transluminal coronary angioplasty: A preliminary comparison to creatine kinase-MB, myoglobin, and troponin I (Bar-Or et al). 2001;141:985-91
- Treatment of focal in-stent restenosis with balloon angioplasty alone versus stenting: Short- and long-term results (Mehran et al). 2001;141:610-14
- Use of routine functional testing after percutaneous transluminal coronary angioplasty: Results from the ROSETTA Registry (Eisenberg et al). 2001;141:837-46
- Angiotensin-converting enzyme inhibitors**
- ADEPT: Addition of the AT₁ receptor antagonist eprosartan to ACE inhibitor therapy in chronic heart failure trial: Hemodynamic and neurohormonal effects (Murdoch et al). 2001;141:800-7
- Angiotensin-converting enzyme inhibitor dosages in elderly patients with heart failure (Chen et al). 2001;141:410-17
- Angiotensin-converting enzyme inhibitor dosing in heart failure: What is optimal? (Gattis et al). 2001;141:331-3 (Editorial)
- An angiotensin-converting enzyme inhibitor improves left ventricular systolic and diastolic function in transfusion-dependent patients with β -thalassemia major (Karvounis et al). 2001;141:e7
- Systemic and renal effects of atrial natriuretic peptide in patients with heart failure treated with angiotensin-converting enzyme inhibitor or in acute saline solution loading (Tomiyama et al). 2001;141:422-7
- Anthracyclines**
- Subclinical cardiotoxic effects of anthracyclines as assessed by magnetic resonance imaging—A pilot study (Wassmuth et al). 2001;141:1007-14
- Antianginal agents; see Vasodilator agents**
- Antibodies**
- Anti-human skeletal muscle glycolipid antibodies in unstable angina (Laguens et al). 2001;141:780-3
- Anticholesteremic agents**
- PRINCE's prospects: Statins, inflammation, and coronary risk (Azar and Waters). 2001;141:881-3 (Editorial)
- Randomized clinical trials and recent patterns in the use of statins (Wang et al). 2001;141:957-63
- Antiplatelet agents; see Platelet aggregation inhibitors**
- Antithrombins, therapeutic; see Fibrinolytic agents**
- Anxiety**
- Depression but not anxiety influences the autonomic control of heart rate after myocardial infarction (Pitzalis et al). 2001;141:765-71
- Aorta**
- Dilation of the aortic root in children infected with human immunodeficiency virus type 1: The Prospective P2C2 HIV Multicenter Study (Lai et al). 2001;141:661-70
- Aortic counterpulsation; see Intra-aortic balloon pumping**
- Aortic valve stenosis**
- Cytomegalovirus in calcific aortic valves (Kennedy et al). 2001;141:e4 (Letter)
- Lack of association among five genetic polymorphisms of the renin-angiotensin system and cardiac hypertrophy in patients with aortic stenosis (Ortlepp et al). 2001;141:671-6
- ARBITER trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol)**
- Design and rationale of the ARBITER trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol)—A randomized trial comparing the effects of atorvastatin and pravastatin on carotid artery intima-media thickness (Markwood et al). 2001;141:342-7 (Trial design)
- Arrhythmia**
- Do baseline characteristics accurately discriminate between patients likely versus unlikely to benefit from implantable defibrillator therapy? (Exner et al). 2001;141:99-104
- Lead- and device-related complications in the Antiarrhythmics Versus Implantable Defibrillators Trial (Kron et al). 2001;141:92-8
- Nicorandil, a potent cardioprotective agent, reduces QT dispersion during coronary angioplasty (Kato et al). 2001;141:940-3
- Predictive value of presyncope in patients monitored for assessment of syncope (Krahn et al). 2001;141:817-21
- QT dispersion: An electrocardiographic derivative of QT prolongation (Krahn et al). 2001;141:111-16
- Arteriosclerosis**
- C-reactive protein is not associated with the presence or extent of calcified subclinical atherosclerosis (Hunt et al). 2001;141:206-10
- Characterization of atherosclerotic plaque by magnetic resonance imaging (Frank). 2001;141:S45-8
- Diabetes and the associated incidence of subclinical atherosclerosis and coronary artery disease: Implications for management (Khaleeli et al). 2001;141:637-44
- Effect of menopause on plaque morphologic characteristics in coronary atherosclerosis (Burke et al). 2001;141:S58-62
- Noninvasive tests of vascular function and structure: Why and how to perform them (Fathi and Marwick). 2001;141:694-703 (Prog. cardi.)
- The smooth muscle cell membrane during atherogenesis: A potential target for amiloridine in atheroprotection (Tulenka et al). 2001;141:S1-11
- Arteriovenous malformations**
- Contrast echocardiography for detection of pulmonary arteriovenous malformations (Nanthakumar et al). 2001;141:243-6
- Aspirin**
- Active-control trials: How would a new agent compare with placebo? A method illustrated with clopidogrel, aspirin, and placebo (Fisher et al). 2001;141:26-32
- Characterization and clinical course of patients not receiving aspirin for acute myocardial infarction: Results from the MITRA and MIR studies (Frilling et al). 2001;141:200-5
- Prior aspirin users with acute non-ST-elevation coronary syndromes are at increased risk of cardiac events and benefit from enoxaparin (Santopinto et al). 2001;141:566-72
- Atherosclerosis; see Arteriosclerosis**
- Atorvastatin**
- Design and rationale of the ARBITER trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol)—A randomized trial comparing the effects of atorvastatin and pravastatin on carotid artery intima-media thickness (Markwood et al). 2001;141:342-7 (Trial design)
- Efficacy of atorvastatin in achieving National Cholesterol Education Program low-density lipoprotein targets in women with severe dyslipidemia and cardiovascular disease or risk factors for cardiovascular disease: The Women's Atorvastatin Trial on Cholesterol (WATCH) (McPherson et al). 2001;141:949-56
- Atrial fibrillation**
- Evolving role of echocardiography in the management of atrial fibrillation (Labovitz and Bransford). 2001;141:518-27 (Curriculum cardi.)

Pharmacologic management of atrial fibrillation: Current therapeutic strategies (Lévy). 2001;141:S15-21

Postoperative atrial fibrillation after heart surgery: What are the goals of prevention? (Kim and Eagle). 2001;141:691-3 (Editorial)

Single-day loading dose of oral amiodarone for the prevention of new-onset atrial fibrillation after coronary artery bypass surgery (Maraš et al). 2001;141:e8

Atrial natriuretic factor

Effects of prolonged strenuous exercise on plasma levels of atrial natriuretic peptide and brain natriuretic peptide in healthy men (Ohba et al). 2001;141:751-8

Systemic and renal effects of atrial natriuretic peptide in patients with heart failure treated with angiotensin-converting enzyme inhibitor or in acute saline solution loading (Tomiyama et al). 2001;141:422-7

Auscultation

Estimation of pressure gradients by auscultation: An innovative and accurate physical examination technique (Phoon). 2001;141:500-6

Autonomic nervous system

Acute effects of melatonin administration on cardiovascular autonomic regulation in healthy men (Nishiyama et al). 2001;141:e9

Depression but not anxiety influences the autonomic control of heart rate after myocardial infarction (Pitzalis et al). 2001;141:765-71

Impairment of cardiac autonomic function in patients with Duchenne muscular dystrophy: Relationship to myocardial and respiratory function (Lanza et al). 2001;141:808-12

B

Beta blockers; see Adrenergic beta-antagonists

Beta-thalassemia

An angiotensin-converting enzyme inhibitor improves left ventricular systolic and diastolic function in transfusion-dependent patients with β -thalassemia major (Karvounis et al). 2001;141:e7

Right ventricular diastolic function in β -thalassemia major: Echocardiographic and clinical correlates (Hahalis et al). 2001;141:428-34

Biological markers

Cardiac enzyme elevations after cardiac surgery: The cardiologist's perspective (Mahaffey and Alpert). 2001;141:321-4 (Editorial)

Early peak creatine kinase activity is not always a marker of successful reperfusion with myocardial salvage in patients with reperfused anterior acute myocardial infarction (Kosuge et al). 2001;141:759-64

Evidence of cardiac myolysis in severe nonischemic heart failure and the potential role of increased wall strain (Logeart et al). 2001;141:247-53

Reduced albumin-cobalt binding with transient myocardial ischemia after elective percutaneous transluminal coronary angioplasty: A preliminary comparison to creatine kinase-MB, myoglobin, and troponin I (Bar-Or et al). 2001;141:985-91

Troponin I in cardiac surgery: Marking the future (Newman). 2001;141:325-6 (Editorial)

Usefulness of cardiac troponin I in patients undergoing open heart surgery (Greenon et al). 2001;141:447-55

Bleeding; see Hemorrhage

Blood glucose

Glycemic control and outcome of diabetic patients after successful percutaneous coronary revascularization (Hasdai et al). 2001;141:117-23

Impaired fasting glucose concentrations in nondiabetic

patients with ischemic heart disease: A marker for a worse prognosis (Fisman et al). 2001;141:485-90

Relationship of impaired glucose tolerance to left ventricular structure and function: The Strong Heart Study (Ilcic et al). 2001;141:992-8

Blood pressure

Estimation of pressure gradients by auscultation: An innovative and accurate physical examination technique (Phoon). 2001;141:500-6

Reproducibility of exaggerated blood pressure response to exercise in healthy patients (Sharabi et al). 2001;141:1007-14

Brain natriuretic peptide; see Natriuretic peptide, brain

C

C-reactive protein

C-reactive protein is not associated with the presence or extent of calcified subclinical atherosclerosis (Hunt et al). 2001;141:206-10

Joint effects of C-reactive protein and other risk factors on acute coronary events (Kervinen et al). 2001;141:580-5

The PRavastatin Inflammation CRP Evaluation (PRINCE): Rationale and design (Albert et al). 2001;141:893-8 (Trial design)

Calcinosis

C-reactive protein is not associated with the presence or extent of calcified subclinical atherosclerosis (Hunt et al). 2001;141:206-10

Do conventional risk factors predict subclinical coronary artery disease? Results from the Prospective Army Coronary Calcium Project (Taylor et al). 2001;141:463-8

Cardiac markers; see Biological markers

Cardiogenic shock; see Shock, cardiogenic

Cardiology

Hippocrates and cardiology (Cheng). 2001;141:173-83 (Curriculum cardiol.)

Cardiomyopathy, congestive

Effect of metoprolol on rest and exercise left ventricular systolic and diastolic function in idiopathic dilated cardiomyopathy (Clements and Miller). 2001;141:e5

Evaluation of β -blocker therapy in patients with dilated cardiomyopathy—Clinical meaning of iodine 123—metaiodobenzylguanidine myocardial single-photon emission computed tomography (Yamazaki et al). 2001; 141:645-52

Increased plasma adhesion molecule levels in patients with heart failure who have ischemic heart disease and dilated cardiomyopathy (Tousoulis et al). 2001;141:277-80

Plasma brain natriuretic peptide as a novel therapeutic indicator in idiopathic dilated cardiomyopathy during β -blocker therapy: A potential of hormone-guided treatment (Kawai et al). 2001;141:925-32

Cardiomyopathy, hypertrophic

Different expressivity of a ventricular essential myosin light chain gene Ala57Gly mutation in familial hypertrophic cardiomyopathy (Lee et al). 2001;141:184-9 (Prog. cardiol.)

Cardiovascular diseases

Diurnal variation and cardiovascular disease (Kamath et al). 2001;141:e3 (Letter)

Efficacy of atorvastatin in achieving National Cholesterol Education Program low-density lipoprotein targets in women with severe dyslipidemia and cardiovascular disease or risk factors for cardiovascular disease: The Women's Atorvastatin Trial on Cholesterol (WATCH) (McPherson et al). 2001;141:949-56

Established and emerging cardiovascular risk factors (Wood). 2001;141:549-57

Carotid arteries

Design and rationale of the ARBITER trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol)—A randomized trial comparing the effects of atorvastatin and pravastatin on carotid artery intima-media thickness (Markwood et al). 2001;141:342-7 (Trial design)

Carvedilol

Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: Results of a meta-analysis (Packer et al). 2001;141:899-907

Catheterization

Early and late reactions after the use of iopamidol 340, ioxaglate 320, and iodixanol 320 in cardiac catheterization (Sutton et al). 2001;141:677-83

Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE): Design and rationale (Shah et al). 2001;141:528-35 (Trial design)

Cell adhesion molecules

Increased plasma adhesion molecule levels in patients with heart failure who have ischemic heart disease and dilated cardiomyopathy (Tousoulis et al). 2001;141:277-80

Chagas disease

Parasympathetic dysautonomia precedes left ventricular systolic dysfunction in Chagas disease (Ribeiro et al). 2001;141:260-5

Chest pain

Coronary microvascular dysfunction is highly prevalent in women with chest pain in the absence of coronary artery disease: Results from the NHLBI WISE study (Reis et al). 2001;141:735-41

Child

Dilation of the aortic root in children infected with human immunodeficiency virus type 1: The Prospective P2C2 HIV Multicenter Study (Lai et al). 2001;141:661-70

Safe and effective for children? (Schreiner and Greeley). 2001;141:3-5 (Editorial)

Cholesterol

Aggressive versus moderate lipid-lowering therapy in postmenopausal women with hypercholesterolemia: Rationale and design of the Beyond Endorsed Lipid Lowering with EBT Scanning (BELLES) trial (Raggi et al). 2001;141:722-6 (Trial design)

Cost-effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels (Tsevat et al). 2001;141:727-34

Efficacy of atorvastatin in achieving National Cholesterol Education Program low-density lipoprotein targets in women with severe dyslipidemia and cardiovascular disease or risk factors for cardiovascular disease: The Women's Atorvastatin Trial on Cholesterol (WATCH) (McPherson et al). 2001;141:949-56

Cilostazol

Effects of cilostazol on late lumen loss and repeat revascularization after Palmaz-Schatz coronary stent implantation (Kozuma et al). 2001;141:124-30

Circadian rhythm

Diurnal variation and cardiovascular disease (Kamath et al). 2001;141:e3 (Letter)

Clinical trials

Active-control trials: How would a new agent compare with placebo? A method illustrated with clopidogrel, aspirin, and placebo (Fisher et al). 2001;141:26-32

Designing trials for testing prosthetic cardiac valves: A Food and Drug Administration perspective (Sapirstein). 2001;141:861-3 (Meetings)

Highlights from the American Heart Association Annual Scientific Sessions 2000: November 12 to 15, 2000 (O'Shea et al). 2001;141:306-18 (Meetings)

Highlights from the XXII Congress of the European Society of

Cardiology: August 26 to 30, 2000 (McGuire et al). 2001;141:164-72 (Meetings)

International differences in cardiovascular clinical trials (O'Shea and Califf). 2001;141:866-74 (Meetings)

International differences in cardiovascular clinical trials—Introduction (O'Shea and Califf). 2001;141:864-5 (Meetings)

International differences in treatment effects in cardiovascular clinical trials (O'Shea and Califf). 2001;141:875-80 (Meetings)

Making changes in clinical trials (Weaver and Greenberg). 2001;141:295-300 (Meetings)

Potential impact of socioeconomic differences on clinical outcomes in international clinical trials (Shibata et al). 2001;141:1019-24 (Meetings)

Randomized clinical trials and recent patterns in the use of statins (Wang et al). 2001;141:957-63

Should all trials have a Data Safety and Monitoring Committee? (Cairns et al). 2001;141:156-63 (Meetings)

Clopidogrel

Active-control trials: How would a new agent compare with placebo? A method illustrated with clopidogrel, aspirin, and placebo (Fisher et al). 2001;141:26-32

Coils; see Equipment and supplies

Collagen

Aldosterone inhibition limits collagen synthesis and progressive left ventricular enlargement after anterior myocardial infarction (Modena et al). 2001;141:41-6

Complement

Serum complement activation in congestive heart failure (Clark et al). 2001;141:684-90

Congenital heart disease; see Heart defects, congenital

Congestive heart failure; see Heart failure, congestive

Contrast media

Clinical applications of contrast echocardiography (Colonna et al). 2001;141:S36-44

Contrast echocardiography for detection of pulmonary arteriovenous malformations (Nanthakumar et al). 2001;141:243-6

Early and late reactions after the use of iopamidol 340, ioxaglate 320, and iodixanol 320 in cardiac catheterization (Sutton et al). 2001;141:677-83

Evaluation of β -blocker therapy in patients with dilated cardiomyopathy—Clinical meaning of iodine 123—metaiodobenzylguanidine myocardial single-photon emission computed tomography (Yamazaki et al). 2001;141:645-52

Coronary artery bypass

Early and late mortality after surgery for unstable angina in relation to Braunwald class (Bjessmo et al). 2001;141:9-14 (Curriculum cardiol.)

Outcome of acute ST-segment elevation myocardial infarction in patients with prior coronary artery bypass surgery receiving thrombolytic therapy (Labinaz et al). 2001;141:469-77

Single-day loading dose of oral amiodarone for the prevention of new-onset atrial fibrillation after coronary artery bypass surgery (Maraš et al). 2001;141:e8

Coronary artery disease; see Coronary disease

Coronary circulation

Corrected TIMI frame counts correlate with stenosis severity and infarct zone wall motion after thrombolytic therapy (Amos et al). 2001;141:586-91

Preserved coronary flow reserve in viable myocardium: Further evidence for the microvascular hypothesis (Angeja and Gibson). 2001;141:329-30 (Editorial)

Relationship between extent of residual myocardial viability and coronary flow reserve in patients with recent myocardial infarction (Ragosta et al). 2001;141:456-62

Coronary disease

And the beat goes on (O'Rourke). 2001;141:319-20 (Editorial)

Diabetes and the associated incidence of subclinical athero-

- sclerosis and coronary artery disease: Implications for management (Khaleeli et al). 2001;141:637-44
- Do conventional risk factors predict subclinical coronary artery disease? Results from the Prospective Army Coronary Calcium Project (Taylor et al). 2001;141:463-8
- Drug therapy or coronary angioplasty for the treatment of coronary artery disease: New insights (Amoroso et al). 2001;141:S22-5
- Established and emerging cardiovascular risk factors (Wood). 2001;141:S49-57
- Prior aspirin users with acute non-ST-elevation coronary syndromes are at increased risk of cardiac events and benefit from enoxaparin (Santopinto et al). 2001;141:566-72
- Updated pathophysiologic concepts in unstable coronary artery disease (Conti). 2001;141:S12-14
- Use of electron beam tomography data to develop models for prediction of hard coronary events (Raggi et al). 2001;141:375-82
- Coronary revascularization; see Myocardial revascularization**
- Coronary vessels**
- Effect of the stenosis location and severity on left ventricular function after single-vessel anterior wall myocardial infarction (Kachi et al). 2001;141:55-64
- Prognostic value of absolute versus relative measures of the procedural result after successful coronary stenting: Importance of vessel size in predicting long-term freedom from target vessel revascularization (Ziada et al). 2001;141:823-31
- Correspondence; see Letters to the Editor**
- Cost-benefit analysis**
- Comparative 30-day economic and clinical outcomes of platelet glycoprotein IIb/IIIa inhibitor use during elective percutaneous coronary intervention: Prairie ReoPro Versus Integrilin Cost Evaluation (PRICE) Trial (PRICE Investigators). 2001;141:402-9
- Cost-effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels (Tsevat et al). 2001;141:727-34
- Creatine kinase; see Biological markers**
- Cytokines**
- Effect of metoprolol on cytokine levels in chronic heart failure—A substudy in the Metoprolol Controlled-Release Randomised Intervention Trial in Heart Failure (MERIT-HF) (Gullestad et al). 2001;141:418-21
- Cytomegalovirus**
- Cytomegalovirus in calcific aortic valves (Kennedy et al). 2001;141:e4 (Letter)
- D**
- Dalteparin; see Tedelparin**
- Data and Safety Monitoring Committees**
- The Data and Safety Monitoring Committee: Some final thoughts (DeMets and Yusuf). 2001;141:548-9 (Meetings)
- Data and safety monitoring committees: Philosophy and practice—Introduction (Califf and Lee). 2001;141:154-5 (Meetings)
- Making changes in clinical trials (Weaver and Greenberg). 2001;141:295-300 (Meetings)
- Procedures of Data and Safety Monitoring Committees (Pocock and Furberg). 2001;141:289-94 (Meetings)
- Regulatory issues for Data and Safety Monitoring Committees (Fisher and Klibanov). 2001;141:536-41 (Meetings)
- Should all trials have a Data Safety and Monitoring Committee? (Cairns et al). 2001;141:156-63 (Meetings)
- Statistical approaches and policies for the operations of Data and Safety Monitoring Committees (Califf and Ellenberg). 2001;141:301-5 (Meetings)
- Terms of reference for Data and Safety Monitoring Committees (Packer et al). 2001;141:542-7 (Meetings)
- Death; see Mortality**
- Defibrillators, implantable**
- Do baseline characteristics accurately discriminate between patients likely versus unlikely to benefit from implantable defibrillator therapy? (Exner et al). 2001;141:99-104
- Lead- and device-related complications in the Antiarrhythmics Versus Implantable Defibrillators Trial (Kron et al). 2001;141:92-8
- Prevalence of central venous occlusion in patients with chronic defibrillator leads (Sticherling et al). 2001;141:813-16
- Delivery of health care**
- Better delivery of standard antithrombotic care (Bussey). 2001;141:1038-42 (Meetings)
- Depression**
- Depression but not anxiety influences the autonomic control of heart rate after myocardial infarction (Pitzalis et al). 2001;141:765-71
- Diabetes mellitus**
- Diabetes and the associated incidence of subclinical atherosclerosis and coronary artery disease: Implications for management (Khaleeli et al). 2001;141:637-44
- Glycemic control and outcome of diabetic patients after successful percutaneous coronary revascularization (Hasdai et al). 2001;141:117-23
- Dipyridamole**
- Safety, feasibility, and prognostic implications of pharmacologic stress echocardiography in 1482 patients evaluated in an ambulatory setting (Cortigiani et al). 2001;141:621-9
- Disease management**
- Heart failure disease management in an indigent population (O'Connell et al). 2001;141:254-8
- Diurnal variation; see Circadian rhythm**
- DNA, mitochondrial**
- The emerging concept of mitochondrial cardiomyopathies (Santorelli et al). 2001;141:e1 (Prog. cardi.)
- Dobutamine**
- Exercise versus dobutamine-induced ST elevation in the infarct-related electrocardiographic leads: Clinical significance and correlation with functional recovery (Lancellotti et al). 2001;141:772-9
- Safety, feasibility, and prognostic implications of pharmacologic stress echocardiography in 1482 patients evaluated in an ambulatory setting (Cortigiani et al). 2001;141:621-9
- Doppler echocardiography; see Echocardiography, Doppler**
- Drug therapy**
- Drug therapy or coronary angioplasty for the treatment of coronary artery disease: New insights (Amoroso et al). 2001;141:S22-5
- Pharmacologic management of atrial fibrillation: Current therapeutic strategies (Lévy). 2001;141:S15-21
- Safe and effective for children? (Schreiner and Greeley). 2001;141:3-5 (Editorial)
- Drug toxicity**
- Subclinical cardiotoxic effects of anthracyclines as assessed by magnetic resonance imaging—A pilot study (Wassmuth et al). 2001;141:1007-14
- Duchenne muscular dystrophy; see Muscular dystrophy, Duchenne**
- Ductus arteriosus, patent**
- Transcatheter closure of persistent arterial ducts with different types of coils (Cheung et al). 2001;141:87-91

E

EBCT; see Tomography, x-ray computed

Echocardiography

- Clinical applications of contrast echocardiography (Colonna et al). 2001;141:536-44
- Contrast echocardiography for detection of pulmonary arteriovenous malformations (Nanthakumar et al). 2001;141:243-6
- Evolving role of echocardiography in the management of atrial fibrillation (Labovitz and Bransford). 2001;141:518-27 (Curriculum cardiol.)
- Regional wall stress predicts ventricular remodeling after anteroapical myocardial infarction in the Healing and Early Afterload Reducing Trial (HEART): An echocardiography-based structural analysis (Aikawa et al). 2001;141:234-42
- Right ventricular diastolic function in β -thalassemia major: Echocardiographic and clinical correlates (Hahalis et al). 2001;141:428-34
- Safety, feasibility, and prognostic implications of pharmacologic stress echocardiography in 1482 patients evaluated in an ambulatory setting (Cortigiani et al). 2001;141:621-9
- Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction (Maisel et al). 2001;141:367-74

Echocardiography, Doppler

- Evaluation and follow-up of patients with left ventricular apical to aortic conduits with 2D and 3D magnetic resonance imaging and Doppler echocardiography: A new look at an old operation (Fogel et al). 2001;141:630-6
- A semiautomated objective technique for applying the proximal isovelocity surface area method to quantitate mitral regurgitation: Clinical studies with the digital flow map (Mele et al). 2001;141:653-60

Editorials

- Aldosterone inhibition and heart failure: Too good to be true? (Francis). 2001;141:1-2
- Angiotensin-converting enzyme inhibitor dosing in heart failure: What is optimal? (Gattis et al). 2001;141:331-3
- Aortic counterpulsation in acute myocardial infarction: Physiologically important but does the patient benefit? (Ohman and Hochman). 2001;141:889-92
- And the beat goes on (O'Rourke). 2001;141:319-20
- Cardiac enzyme elevations after cardiac surgery: The cardiologist's perspective (Mahaffey and Alpert). 2001;141:321-4
- Factors affecting long-term mortality in endocarditis: The bugs, the drugs, the knife...or the patients? (Cabell and Peterson). 2001;141:6-8
- Need for standardization of noninvasive assessment of vascular endothelial function (Kuvin et al). 2001;141:327-8
- Postoperative atrial fibrillation after heart surgery: What are the goals of prevention? (Kim and Eagle). 2001;141:691-3
- Preserved coronary flow reserve in viable myocardium: Further evidence for the microvascular hypothesis (Angeles and Gibson). 2001;141:329-30
- PRINCE's prospects: Statins, inflammation, and coronary risk (Azar and Waters). 2001;141:881-3
- Safe and effective for children? (Schreiner and Greeley). 2001;141:3-5
- Troponin I in cardiac surgery: Marking the future (Newman). 2001;141:325-6
- Which β -blocker for heart failure? (Adams). 2001;141:884-8

Ejection fraction; see Stroke volume

Elderly; see Aged

Electrocardiography

- The absence of high-frequency QRS changes in the presence of standard electrocardiographic QRS changes of old myocardial infarction (Ringborn et al). 2001;141:573-9

- Clinical significance of ST-segment elevation in lead V1 in patients with acute inferior wall Q-wave myocardial infarction (Tsuka et al). 2001;141:615-20
- Does the presence of hibernating myocardium in patients with impaired left ventricular contraction affect QT dispersion? (Al Mohammad et al). 2001;141:944-8
- Electrocardiographic diagnosis of acute myocardial infarction: Current concepts for the clinician (Sgarbossa et al). 2001;141:507-17 (Curriculum cardiol.)
- Exercise versus dobutamine-induced ST elevation in the infarct-related electrocardiographic leads: Clinical significance and correlation with functional recovery (Lancellotti et al). 2001;141:772-9
- Nicorandil, a potent cardioprotective agent, reduces QT dispersion during coronary angioplasty (Kato et al). 2001;141:xx10
- A nonischemic electrocardiogram does not always predict a small myocardial infarction: Results with acute myocardial perfusion imaging (Kontos et al). 2001;141:360-6
- Prediction of the extent and severity of left ventricular dysfunction in anterior acute myocardial infarction by the admission electrocardiogram (Birnbau et al). 2001;141:915-24
- QT dispersion: An electrocardiographic derivative of QT prolongation (Kahn et al). 2001;141:111-16

Electron beam tomography; see Tomography, x-ray computed

Endocarditis

- Factors affecting long-term mortality in endocarditis: The bugs, the drugs, the knife...or the patients? (Cabell and Peterson). 2001;141:6-8 (Editorial)
- Relapses, recurrences, valve replacements, and mortality during the long-term follow-up after infective endocarditis (Mansur et al). 2001;141:78-86

Endothelium, vascular

- Need for standardization of noninvasive assessment of vascular endothelial function (Kuvin et al). 2001;141:327-8 (Editorial)
- Noninvasive tests of vascular function and structure: Why and how to perform them (Fathi and Marwick). 2001;141:694-703 (Prog. cardiol.)

Enoxaparin

- Prior aspirin users with acute non-ST-elevation coronary syndromes are at increased risk of cardiac events and benefit from enoxaparin (Santopinto et al). 2001;141:566-72

EPIC, EPILOG, and EPISTENT

- Effect of smoking status and abciximab use on outcome after percutaneous coronary revascularization: Pooled analysis from EPIC, EPILOG, and EPISTENT (Cho et al). 2001;141:599-602

Eprosartan

- ADEPT: Addition of the AT₁ receptor antagonist eprosartan to ACE inhibitor therapy in chronic heart failure trial: Hemodynamic and neurohormonal effects (Murdoch et al). 2001;141:800-7

Equipment and supplies

- Transcatheter closure of persistent arterial ducts with different types of coils (Cheung et al). 2001;141:87-91

Estrogen

- Effect of menopause on plaque morphologic characteristics in coronary atherosclerosis (Burke et al). 2001;141:558-62

European Society of Cardiology

- Highlights from the XXII Congress of the European Society of Cardiology: August 26 to 30, 2000 (McGuire et al). 2001;141:164-72 (Meetings)

Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE)

- Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE): Design and rationale (Shah et al). 2001;141:528-35 (Trial design)

Exercise

- Detection of changes in diastolic function by pulmonary venous flow analysis in women athletes (Guazzi et al). 2001;141:139-47
- Effect of metoprolol on rest and exercise left ventricular systolic and diastolic function in idiopathic dilated cardiomyopathy (Clements and Miller). 2001;141:e5
- Effects of prolonged strenuous exercise on plasma levels of atrial natriuretic peptide and brain natriuretic peptide in healthy men (Ohba et al). 2001;141:751-8

Exercise test

- Evidence suggesting coronary vasodilation as the principal mechanism in the warm-up phenomenon (Ylitalo et al). 2001;141:e10
- Exercise versus dobutamine-induced ST elevation in the infarct-related electrocardiographic leads: Clinical significance and correlation with functional recovery (Lancellotti et al). 2001;141:772-9
- Reproducibility of exaggerated blood pressure response to exercise in healthy patients (Sharabi et al). 2001;141:1014-7
- Ten-year mortality rate in relation to observations at a bicycle exercise test in patients with a suspected or confirmed ischemic event but no or only minor myocardial damage: Influence of subsequent revascularization (Karlsen et al). 2001;141:977-84
- Use of routine functional testing after percutaneous transluminal coronary angioplasty: Results from the ROSETTA Registry (Eisenberg et al). 2001;141:837-46

F**Fibrinolytic agents**

- Antithrombotic therapy after prosthetic cardiac valve implantation: Improving postoperative, long-term patient management—Introduction (Berkowitz). 2001;141:847-8 (Meetings)
- Better delivery of standard antithrombotic care (Bussey). 2001;141:xx25 (Meeting)
- Direct thrombin inhibitors in acute coronary syndromes and during percutaneous coronary intervention: Design of a meta-analysis based on individual patient data (Direct Thrombin Inhibitor Trialists' Collaborative Group). 2001;141:e2 (Trial design)
- Lower-dose heparin with fibrinolysis is associated with lower rates of intracranial hemorrhage (Giugliano et al). 2001;141:742-50
- Novel intravenous antithrombins (Levy). 2001;141:1043-7 (Meetings)

FIRST

- Hemodynamics as surrogate end points for survival in advanced heart failure: An analysis from FIRST (Shah et al). 2001;141:908-14

Food and Drug Administration; see United States Food and Drug Administration**G****Genes**

- Different expressivity of a ventricular essential myosin light chain gene Ala57Gly mutation in familial hypertrophic cardiomyopathy (Lee et al). 2001;141:184-9 (Prog. cardiol.)
- Lack of association among five genetic polymorphisms of the renin-angiotensin system and cardiac hypertrophy in patients with aortic stenosis (Ortlepp et al). 2001;141:671-6

Glucose, blood; see Blood glucose**Glycolipids**

- Anti-human skeletal muscle glycolipid antibodies in unstable angina (Laguens et al). 2001;141:780-3

Glycoprotein IIb/IIIa complex inhibitors; see Platelet aggregation inhibitors**GRACE (Global Registry of Acute Coronary Events) Project**

- Rationale and design of the GRACE (Global Registry of Acute Coronary Events) Project: A multinational registry of patients hospitalized with acute coronary syndromes (GRACE Investigators). 2001;141:190-9 (Trial design)

H**Healing and Early Afterload Reducing Trial (HEART)**

- Regional wall stress predicts ventricular remodeling after antero-septal myocardial infarction in the Healing and Early Afterload Reducing Trial (HEART): An echocardiography-based structural analysis (Aikawa et al). 2001;141:234-42

Health policy

- Regulatory issues for Data and Safety Monitoring Committees (Fisher and Klibaner). 2001;141:536-41 (Meetings)

Heart block

- Acute myocardial infarction complicated by heart block in the elderly: Prevalence and outcomes (Rathore et al). 2001;141:47-54

Heart defects, congenital

- Congenital left ventricular aneurysm: Clinical, imaging, pathologic, and surgical findings in seven new cases (Papagiannis et al). 2001;141:491-9

Heart disease, ischemic; see Myocardial ischemia**Heart failure, congestive, drug therapy**

- ADEPT: Addition of the AT₁ receptor antagonist eprosartan to ACE inhibitor therapy in chronic heart failure trial: Hemodynamic and neurohormonal effects (Murdoch et al). 2001;141:800-7
- Aldosterone inhibition and heart failure: Too good to be true? (Francis). 2001;141:1-2 (Editorial)
- Angiotensin-converting enzyme inhibitor dosages in elderly patients with heart failure (Chen et al). 2001;141:410-17
- Angiotensin-converting enzyme inhibitor dosing in heart failure: What is optimal? (Gattis et al). 2001;141:331-3 (Editorial)
- Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: Results of a meta-analysis (Packer et al). 2001;141:899-907
- Effect of metoprolol on cytokine levels in chronic heart failure—A substudy in the Metoprolol Controlled-Release Randomised Intervention Trial in Heart Failure (MERIT-HF) (Gullestad et al). 2001;141:418-21
- Pharmacodynamic effects of milrinone with and without a bolus loading infusion (Baruch et al). 2001;141:e6
- Systemic and renal effects of atrial natriuretic peptide in patients with heart failure treated with angiotensin-converting enzyme inhibitor or in acute saline solution loading (Tomiyama et al). 2001;141:422-7
- Which β -blocker for heart failure? (Adams). 2001;141:884-8 (Editorial)

Heart failure, congestive, pathophysiology

- Evidence of cardiac myolysis in severe nonischemic heart failure and the potential role of increased wall strain (Logeart et al). 2001;141:247-53
- Serum complement activation in congestive heart failure (Clark et al). 2001;141:684-90
- Uric acid in cachectic and noncachectic patients with chronic heart failure: Relationship to leg vascular resistance (Doehner et al). 2001;141:792-9

Heart failure, congestive, therapy

- Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE): Design and rationale (Shah et al). 2001;141:528-35 (Trial design)
- Heart failure disease management in an indigent population (O'Connell et al). 2001;141:254-8
- Hemodynamics as surrogate end points for survival in advanced heart failure: An analysis from FIRST (Shah et al). 2001;141:908-14

Heart rate

- Depression but not anxiety influences the autonomic control of heart rate after myocardial infarction (Pitzalis et al). 2001;141:765-71
- Impairment of cardiac autonomic function in patients with Duchenne muscular dystrophy: Relationship to myocardial and respiratory function (Lanza et al). 2001;141:808-12

Heart valve prosthesis

- Antithrombotic therapy after prosthetic cardiac valve implantation: Improving postoperative, long-term patient management—Introduction (Berkowitz). 2001;141:847-8 (Meetings)
- Better delivery of standard antithrombotic care (Bussey). 2001;141:1038-42 (Meetings)
- Designing trials for testing prosthetic cardiac valves: A Food and Drug Administration perspective (Sapirstein). 2001;141:861-3 (Meetings)
- Evolution of prosthetic heart valves (Edmunds). 2001;141:849-55 (Meetings)
- The "ideal" replacement heart valve (Sapirstein and Smith). 2001;141:856-60 (Meetings)
- Pathobiologic features and prevention of thrombotic complications associated with prosthetic heart valves: Fundamental principles and the contribution of platelets and thrombin (Becker et al). 2001;141:1025-37 (Meetings)
- Relapses, recurrences, valve replacements, and mortality during the long-term follow-up after infective endocarditis (Mansur et al). 2001;141:78-86

Hemodynamics

- Hemodynamics as surrogate end points for survival in advanced heart failure: An analysis from FIRST (Shah et al). 2001;141:908-14

Hemorrhage

- Bleeding risks with abciximab after full-dose thrombolysis in rescue or urgent angioplasty for acute myocardial infarction (Jong et al). 2001;141:218-25

Heparin

- Lower-dose heparin with fibrinolysis is associated with lower rates of intracranial hemorrhage (Giugliano et al). 2001;141:742-50

Hippocrates

- Hippocrates and cardiology (Cheng). 2001;141:173-83 (Curriculum cardiol.)

HIV-1

- Dilation of the aortic root in children infected with human immunodeficiency virus type 1: The Prospective P2C2 HIV Multicenter Study (Lai et al). 2001;141:661-70

Hibernating myocardium; see Myocardial stunning

Hypertension

- Left ventricular function and hemodynamic features of inappropriate left ventricular hypertrophy in patients with systemic hypertension: The LIFE Study (Palmieri et al). 2001;141:784-91

Hypertrophy, left ventricular

- Aldosterone inhibition limits collagen synthesis and progressive left ventricular enlargement after anterior myocardial infarction (Modena et al). 2001;141:41-6
- Lack of association among five genetic polymorphisms of the renin-angiotensin system and cardiac hypertrophy in patients with aortic stenosis (Ortlepp et al). 2001;141:671-6
- Left ventricular function and hemodynamic features of inappropriate left ventricular hypertrophy in patients with systemic hypertension: The LIFE Study (Palmieri et al). 2001;141:784-91

appropriate left ventricular hypertrophy in patients with systemic hypertension: The LIFE Study (Palmieri et al). 2001;141:784-91

Prognostic implications of left ventricular hypertrophy (Vakili et al). 2001;141:334-41 (Prog. cardiol.)

I

IAPB; see Intra-aortic balloon pumping

Infant

- Amiodarone is safe and highly effective therapy for supraventricular tachycardia in infants (Etheridge et al). 2001;141:105-10

Infective endocarditis; see Endocarditis

Inflammation

- The PRavastatin Inflammation CRP Evaluation (PRINCE): Rationale and design (Albert et al). 2001;141:893-8 (Trial design)
- PRINCE's prospects: Statins, inflammation, and coronary risk (Azar and Waters). 2001;141:881-3 (Editorial)

Infusions, intravenous

- Novel intravenous antithrombins (Levy). 2001;141:1043-9 (Meetings)
- Pharmacodynamic effects of milrinone with and without a bolus loading infusion (Baruch et al). 2001;141:e6

INTER-HEART

- INTER-HEART: A global study of risk factors for acute myocardial infarction (Ounpuu et al). 2001;141:711-21 (Prog. cardiol.)

Interleukin-6

- Elevated interleukin-6 levels in patients with asymptomatic left ventricular systolic dysfunction (Raymond et al). 2001;141:435-8

Intra-aortic balloon pumping

- Aortic counterpulsation in acute myocardial infarction: Physiologically important but does the patient benefit? (Ohman and Hochman). 2001;141:889-92 (Editorial)
- The use of intra-aortic balloon counterpulsation in patients with cardiogenic shock complicating acute myocardial infarction: Data from the National Registry of Myocardial Infarction 2 (Barron et al). 2001;141:933-9

Intracranial hemorrhages

- Lower-dose heparin with fibrinolysis is associated with lower rates of intracranial hemorrhage (Giugliano et al). 2001;141:742-50

Intraoperative complications

- Cardiac enzyme elevations after cardiac surgery: The cardiologist's perspective (Mahaffey and Alpert). 2001;141:321-4 (Editorial)
- Troponin I in cardiac surgery: Marking the future (Newman). 2001;141:325-6 (Editorial)
- Usefulness of cardiac troponin I in patients undergoing open heart surgery (Greenon et al). 2001;141:447-55

Intravascular ultrasound; see Ultrasonography, interventional

Intravenous infusions; see Infusions, intravenous

Iodine 123-metaiodobenzylguanidine; see Contrast media

Iopamidol 340; see Contrast media

Ischemic heart disease; see Myocardial ischemia

Ischemic preconditioning

- Nicorandil, a potent cardioprotective agent, reduces QT dispersion during coronary angioplasty (Kato et al). 2001;141:940-3

L

Letters to the Editor

- Cytomegalovirus in calcific aortic valves (Kennedy et al). 2001;141:e4

Diurnal variation and cardiovascular disease (Kamath et al). 2001;141:e3

LIFE Study

Left ventricular function and hemodynamic features of inappropriate left ventricular hypertrophy in patients with systemic hypertension: The LIFE Study (Palmieri et al). 2001;141:784-91

M

Magnetic resonance imaging

Characterization of atherosclerotic plaque by magnetic resonance imaging (Frank). 2001;141:S45-8
Evaluation and follow-up of patients with left ventricular apical to aortic conduits with 2D and 3D magnetic resonance imaging and Doppler echocardiography: A new look at an old operation (Fogel et al). 2001;141:630-6
Subclinical cardiotoxic effects of anthracyclines as assessed by magnetic resonance imaging—A pilot study (Wassmuth et al). 2001;141:1007-13

Matrix metalloproteinases

Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome (Inokubo et al). 2001;141:211-17

Melatonin

Acute effects of melatonin administration on cardiovascular autonomic regulation in healthy men (Nishiyama et al). 2001;141:e9

Men

Acute effects of melatonin administration on cardiovascular autonomic regulation in healthy men (Nishiyama et al). 2001;141:e9
Effects of prolonged strenuous exercise on plasma levels of atrial natriuretic peptide and brain natriuretic peptide in healthy men (Ohba et al). 2001;141:751-8
Unstable angina in the Myocardial Infarction Triage and Intervention Registry (MITI): Short- and long-term outcomes in men and women (Kim et al). 2001;141:73-7

Menopause

Aggressive versus moderate lipid-lowering therapy in postmenopausal women with hypercholesterolemia: Rationale and design of the Beyond Endorsed Lipid Lowering with EBT Scanning (BELLES) trial (Raggi et al). 2001;141:722-6 (Trial design)
Effect of menopause on plaque morphologic characteristics in coronary atherosclerosis (Burke et al). 2001;141:S58-62

Metoprolol

Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: Results of a meta-analysis (Packer et al). 2001;141:899-907
Effect of metoprolol on cytokine levels in chronic heart failure—A substudy in the Metoprolol Controlled-Release Randomised Intervention Trial in Heart Failure (MERIT-HF) (Gullestad et al). 2001;141:418-21
Effect of metoprolol on rest and exercise left ventricular systolic and diastolic function in idiopathic dilated cardiomyopathy (Clements and Miller). 2001;141:e5

Microcirculation

Coronary microvascular dysfunction is highly prevalent in women with chest pain in the absence of coronary artery disease: Results from the NHLBI WISE study (Reis et al). 2001;141:735-41
Preserved coronary flow reserve in viable myocardium: Further evidence for the microvascular hypothesis (Angeja and Gibson). 2001;141:329-30 (Editorial)

Milrinone

Pharmacodynamic effects of milrinone with and without a bolus loading infusion (Baruch et al). 2001;141:e6

MIR and MITRA studies

Characterization and clinical course of patients not receiving aspirin for acute myocardial infarction: Results from the MITRA and MIR studies (Frilling et al). 2001;141:200-5

Mitochondrial myopathies

The emerging concept of mitochondrial cardiomyopathies (Santorelli et al). 2001;141:e1 (Prog. cardiol.)

Mitral valve insufficiency

A semiautomated objective technique for applying the proximal isovelocity surface area method to quantitate mitral regurgitation: Clinical studies with the digital flow map (Mele et al). 2001;141:653-60

Mortality

Early and late mortality after surgery for unstable angina in relation to Braunwald class (Bjessmo et al). 2001;141:9-14 (Curriculum cardiol.)
Factors affecting long-term mortality in endocarditis: The bugs, the drugs, the knife...or the patients? (Cabell and Peterson). 2001;141:6-8 (Editorial)
Perioperative β -blocker withdrawal and mortality in vascular surgical patients (Shammash et al). 2001;141:148-53
Recent magnitude of and temporal trends (1994-1997) in the incidence and hospital death rates of cardiogenic shock complicating acute myocardial infarction: The second National Registry of Myocardial Infarction (Goldberg et al). 2001;141:65-72
Relapses, recurrences, valve replacements, and mortality during the long-term follow-up after infective endocarditis (Mansur et al). 2001;141:78-86
Ten-year mortality rate in relation to observations at a bicycle exercise test in patients with a suspected or confirmed ischemic event but no or only minor myocardial damage: Influence of subsequent revascularization (Karlson et al). 2001;141:977-84

MRI; see Magnetic resonance imaging

Muscle, smooth, vascular

The smooth muscle cell membrane during atherogenesis: A potential target for amlodipine in atheroprotection (Tulenko et al). 2001;141:S1-11

Muscular dystrophy, Duchenne

Impairment of cardiac autonomic function in patients with Duchenne muscular dystrophy: Relationship to myocardial and respiratory function (Lanza et al). 2001;141:808-12

Myocardial infarction, diagnosis

The absence of high-frequency QRS changes in the presence of standard electrocardiographic QRS changes of old myocardial infarction (Ringborn et al). 2001;141:573-9
Cardiac enzyme elevations after cardiac surgery: The cardiologist's perspective (Mahaffey and Alpert). 2001;141:321-4 (Editorial)
Clinical significance of ST-segment elevation in lead V1 in patients with acute inferior wall Q-wave myocardial infarction (Tsuka et al). 2001;141:615-20
Electrocardiographic diagnosis of acute myocardial infarction: Current concepts for the clinician (Sgarbossa et al). 2001;141:507-17 (Curriculum cardiol.)
A nonischemic electrocardiogram does not always predict a small myocardial infarction: Results with acute myocardial perfusion imaging (Kontos et al). 2001;141:360-6
Troponin I in cardiac surgery: Marking the future (Newman). 2001;141:325-6 (Editorial)
Usefulness of cardiac troponin I in patients undergoing open heart surgery (Greenon et al). 2001;141:447-55

Myocardial infarction, drug therapy

Aldosterone inhibition limits collagen synthesis and progressive left ventricular enlargement after anterior myocardial infarction (Modena et al). 2001;141:41-6
Characterization and clinical course of patients not receiving aspirin for acute myocardial infarction: Results from the MITRA and MIR studies (Frilling et al). 2001;141:200-5

- Cost-effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels (Tsevat et al). 2001;141:727-34
- Determination of a weight-adjusted dose of TNK-tissue plasminogen activator (Wang-Clow et al). 2001;141:33-40
- Direct thrombin inhibitors in acute coronary syndromes and during percutaneous coronary intervention: Design of a meta-analysis based on individual patient data (Direct Thrombin Inhibitor Trialists' Collaborative Group). 2001; 141:e2 (Trial design)

Myocardial infarction, epidemiology

- INTER-HEART: A global study of risk factors for acute myocardial infarction (Öunpuu et al). 2001;141:711-21 (Prog. cardiol.)
- Rationale and design of the GRACE (Global Registry of Acute Coronary Events) Project: A multinational registry of patients hospitalized with acute coronary syndromes (GRACE Investigators). 2001;141:190-9 (Trial design)
- Recent magnitude of and temporal trends (1994-1997) in the incidence and hospital death rates of cardiogenic shock complicating acute myocardial infarction: The second National Registry of Myocardial Infarction (Goldberg et al). 2001;141:65-72
- Use of electron beam tomography data to develop models for prediction of hard coronary events (Raggi et al). 2001; 141:375-82

Myocardial infarction, pathophysiology

- Acute myocardial infarction complicated by heart block in the elderly: Prevalence and outcomes (Rathore et al). 2001; 141:47-54
- Depression but not anxiety influences the autonomic control of heart rate after myocardial infarction (Pitzalis et al). 2001;141:765-71
- Effect of the stenosis location and severity on left ventricular function after single-vessel anterior wall myocardial infarction (Kachi et al). 2001;141:55-64
- Heterogeneity of left ventricular remodeling after acute myocardial infarction: Results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-3 Echo Substudy (Giannuzzi et al). 2001;141:131-8
- Joint effects of C-reactive protein and other risk factors on acute coronary events (Kervinen et al). 2001;141:580-5
- Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome (Inokubo et al). 2001;141:211-17
- Recurrent ischemia after thrombolysis for acute myocardial infarction (Pilote et al). 2001;141:559-65
- Relationship between extent of residual myocardial viability and coronary flow reserve in patients with recent myocardial infarction (Ragosta et al). 2001;141:456-62

Myocardial infarction, prognosis

- Exercise versus dobutamine-induced ST elevation in the infarct-related electrocardiographic leads: Clinical significance and correlation with functional recovery (Lancellotti et al). 2001;141:772-9
- Outcome of acute ST-segment elevation myocardial infarction in patients with prior coronary artery bypass surgery receiving thrombolytic therapy (Labinaz et al). 2001; 141:469-77
- Prediction of the extent and severity of left ventricular dysfunction in anterior acute myocardial infarction by the admission electrocardiogram (Birbaum et al). 2001;141:915-24
- Prognosis of patients with a recurrent acute myocardial infarction before and in the reperfusion era—A national study (Shotan et al). 2001;141:478-84

Myocardial infarction, therapy

- Aortic counterpulsation in acute myocardial infarction: Physiologically important but does the patient benefit? (Ohman and Hochman). 2001;141:889-92 (Editorial)

- Bleeding risks with abciximab after full-dose thrombolysis in rescue or urgent angioplasty for acute myocardial infarction (Jong et al). 2001;141:218-25
- Coronary stenting and platelet glycoprotein IIb/IIIa receptor blockade in acute myocardial infarction (Santoro and Bolognese). 2001;141:S26-35
- Corrected TIMI frame counts correlate with stenosis severity and infarct zone wall motion after thrombolytic therapy (Amos et al). 2001;141:586-91
- Early peak creatine kinase activity is not always a marker of successful reperfusion with myocardial salvage in patients with reperfused anterior acute myocardial infarction (Kosuge et al). 2001;141:759-64
- Improved survival of patients with acute myocardial infarction with significant left ventricular dysfunction undergoing invasive coronary procedures (Rott et al). 2001;141: 267-76
- Infarct artery reocclusion after primary angioplasty, stent placement, and thrombolytic therapy for acute myocardial infarction (Wilson et al). 2001;141:704-10 (Prog. cardiol.)
- Influence of treatment delay on long-term left ventricular function in patients with acute myocardial infarction successfully treated with primary angioplasty (Sheiban et al). 2001;141:603-9
- Interventional procedures in acute myocardial infarction (DeGeare et al). 2001;141:15-24 (Curriculum cardiol.)
- Rheolytic thrombectomy during percutaneous revascularization for acute myocardial infarction: Experience with the Angiojet catheter (Silva et al). 2001;141:353-9
- Variation in patient management and outcomes for acute coronary syndromes in Latin America and North America: Results from the Platelet IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial (Cohen et al). 2001;141:391-401

Myocardial Infarction Triage and Intervention Registry (MITI)

- Unstable angina in the Myocardial Infarction Triage and Intervention Registry (MITI): Short- and long-term outcomes in men and women (Kim et al). 2001;141:73-7

Myocardial ischemia

- Impaired fasting glucose concentrations in nondiabetic patients with ischemic heart disease: A marker for a worse prognosis (Fisman et al). 2001;141:485-90
- Increased plasma adhesion molecule levels in patients with heart failure who have ischemic heart disease and dilated cardiomyopathy (Tousoulis et al). 2001;141:277-80
- Recurrent ischemia after thrombolysis for acute myocardial infarction (Pilote et al). 2001;141:559-65
- Reduced albumin-cobalt binding with transient myocardial ischemia after elective percutaneous transluminal coronary angioplasty: A preliminary comparison to creatine kinase-MB, myoglobin, and troponin I (Bar-Or et al). 2001;141:985-91
- Ten-year mortality rate in relation to observations at a bicycle exercise test in patients with a suspected or confirmed ischemic event but no or only minor myocardial damage: Influence of subsequent revascularization (Karlson et al). 2001;141:977-84

Myocardial revascularization

- Effects of cilostazol on late lumen loss and repeat revascularization after Palmaz-Schatz coronary stent implantation (Kozuma et al). 2001;141:124-30
- Glycemic control and outcome of diabetic patients after successful percutaneous coronary revascularization (Hasdai et al). 2001;141:117-23
- Prognostic value of absolute versus relative measures of the procedural result after successful coronary stenting: Importance of vessel size in predicting long-term freedom from target vessel revascularization (Ziada et al). 2001; 141:823-31

- Rheolytic thrombectomy during percutaneous revascularization for acute myocardial infarction: Experience with the Angiojet catheter (Silva et al). 2001;141:353-9
- Ten-year mortality rate in relation to observations at a bicycle exercise test in patients with a suspected or confirmed ischemic event but no or only minor myocardial damage: Influence of subsequent revascularization (Karlsen et al). 2001;141:977-84

Myocardial stunning

- Does the presence of hibernating myocardium in patients with impaired left ventricular contraction affect QT dispersion? (Al Mohammad et al). 2001;141:944-8

Myocardium

- Evidence of cardiac myolysis in severe nonischemic heart failure and the potential role of increased wall strain (Logeart et al). 2001;141:247-53
- Preserved coronary flow reserve in viable myocardium: Further evidence for the microvascular hypothesis (Angeja and Gibson). 2001;141:329-30 (Editorial)
- Relationship between extent of residual myocardial viability and coronary flow reserve in patients with recent myocardial infarction (Ragosta et al). 2001;141:456-62

Myoglobin; see Biological markers

Myosin light chains

- Different expressivity of a ventricular essential myosin light chain gene Ala57Gly mutation in familial hypertrophic cardiomyopathy (Lee et al). 2001;141:184-9 (Prog. cardiol.)

N

National Registry of Myocardial Infarction 2

- Recent magnitude of and temporal trends (1994-1997) in the incidence and hospital death rates of cardiogenic shock complicating acute myocardial infarction: The second National Registry of Myocardial Infarction (Goldberg et al). 2001;141:65-72
- The use of intra-aortic balloon counterpulsation in patients with cardiogenic shock complicating acute myocardial infarction: Data from the National Registry of Myocardial Infarction 2 (Barron et al). 2001;141:933-9

Natriuretic peptide, atrial; see Atrial natriuretic factor

Natriuretic peptide, brain

- Effects of prolonged strenuous exercise on plasma levels of atrial natriuretic peptide and brain natriuretic peptide in healthy men (Ohba et al). 2001;141:751-8
- Plasma brain natriuretic peptide as a novel therapeutic indicator in idiopathic dilated cardiomyopathy during β -blocker therapy: A potential of hormone-guided treatment (Kawai et al). 2001;141:925-32
- Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction (Maisel et al). 2001;141:367-74

Nicorandil

- Nicorandil, a potent cardioprotective agent, reduces QT dispersion during coronary angioplasty (Kato et al). 2001;141:940-3

O

Outcome assessment (health care)

- Comparative 30-day economic and clinical outcomes of platelet glycoprotein IIb/IIIa inhibitor use during elective percutaneous coronary intervention: Prairie ReoPro Versus Integrilin Cost Evaluation (PRICE) Trial (PRICE Investigators). 2001;141:402-9

- International differences in treatment effects in cardiovascular clinical trials (O'Shea and Califf). 2001;141:875-80 (Meetings)

- Potential impact of socioeconomic differences on clinical outcomes in international clinical trials (Shibata et al). 2001;141:1019-24 (Meetings)

- Unstable angina in the Myocardial Infarction Triage and Intervention Registry (MITI): Short- and long-term outcomes in men and women (Kim et al). 2001;141:73-7
- Variation in patient management and outcomes for acute coronary syndromes in Latin America and North America: Results from the Platelet IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial (Cohen et al). 2001;141:391-401

P

Palmaz-Schatz stent; see Stents

Parasympathetic nervous system

- Parasympathetic dysautonomia precedes left ventricular systolic dysfunction in Chagas disease (Ribeiro et al). 2001;141:260-5

Patent ductus arteriosus; see Ductus arteriosus, patent

Pediatric patient; see Child

Perfusion

- Gated single-photon emission computed tomographic myocardial imaging: A new tool in clinical cardiology (Bavelaar-Croon et al). 2001;141:383-90
- A nonischemic electrocardiogram does not always predict a small myocardial infarction: Results with acute myocardial perfusion imaging (Kontos et al). 2001;141:360-6

Persistent arterial ducts; see Ductus arteriosus, patent

Physical examination

- Estimation of pressure gradients by auscultation: An innovative and accurate physical examination technique (Phoon). 2001;141:500-6

Placebo effect

- Active-control trials: How would a new agent compare with placebo? A method illustrated with clopidogrel, aspirin, and placebo (Fisher et al). 2001;141:26-32

Platelet aggregation inhibitors

- Comparative 30-day economic and clinical outcomes of platelet glycoprotein IIb/IIIa inhibitor use during elective percutaneous coronary intervention: Prairie ReoPro Versus Integrilin Cost Evaluation (PRICE) Trial (PRICE Investigators). 2001;141:402-9
- Coronary stenting and platelet glycoprotein IIb/IIIa receptor blockade in acute myocardial infarction (Santoro and Bolognese). 2001;141:526-35
- Rapid assessment of glycoprotein IIb/IIIa blockade with the platelet function analyzer (PFA-100) during percutaneous coronary intervention (Madan et al). 2001;141:226-33

Platelet function tests

- Rapid assessment of glycoprotein IIb/IIIa blockade with the platelet function analyzer (PFA-100) during percutaneous coronary intervention (Madan et al). 2001;141:226-33

Platelet IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial

- Variation in patient management and outcomes for acute coronary syndromes in Latin America and North America: Results from the Platelet IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial (Cohen et al). 2001;141:391-401

Polymorphism (genetics)

- Lack of association among five genetic polymorphisms of the renin-angiotensin system and cardiac hypertrophy in

patients with aortic stenosis (Ortlepp et al). 2001;141:671-6

Postoperative complications

Lead- and device-related complications in the Antiarrhythmics Versus Implantable Defibrillators Trial (Kron et al). 2001;141:92-8

Postoperative atrial fibrillation after heart surgery: What are the goals of prevention? (Kim and Eagle). 2001;141:691-3 (Editorial)

Poverty; see Socioeconomic factors

Prairie ReoPro Versus Integrilin Cost Evaluation (PRICE) Trial

Comparative 30-day economic and clinical outcomes of platelet glycoprotein IIb/IIIa inhibitor use during elective percutaneous coronary intervention: Prairie ReoPro Versus Integrilin Cost Evaluation (PRICE) Trial (PRICE Investigators). 2001;141:402-9

Pravastatin

Cost-effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels (Tsevat et al). 2001;141:727-34

Design and rationale of the ARBITER trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol)—A randomized trial comparing the effects of atorvastatin and pravastatin on carotid artery intima-media thickness (Markwood et al). 2001;141:342-7 (Trial design)

Pravastatin Inflammation CRP Evaluation (PRINCE)

The Pravastatin Inflammation CRP Evaluation (PRINCE): Rationale and design (Albert et al). 2001;141:893-8 (Trial design)

PRINCE's prospects: Statins, inflammation, and coronary risk (Azar and Waters). 2001;141:881-3 (Editorial)

Presyncope; see Syncope

Prognosis

Impaired fasting glucose concentrations in nondiabetic patients with ischemic heart disease: A marker for a worse prognosis (Fisman et al). 2001;141:485-90

Long-term prognostic value of ²⁰¹Tl single-photon emission computed tomographic myocardial perfusion imaging after coronary stenting (Cottin et al). 2001;141:999-1006

Prognosis of patients with a recurrent acute myocardial infarction before and in the reperfusion era—A national study (Shotan et al). 2001;141:478-84

Prognostic implications of left ventricular hypertrophy (Vakili et al). 2001;141:334-41 (Prog. cardiol.)

Prognostic value of absolute versus relative measures of the procedural result after successful coronary stenting: Importance of vessel size in predicting long-term freedom from target vessel revascularization (Ziada et al). 2001;141:823-31

Safety, feasibility, and prognostic implications of pharmacologic stress echocardiography in 1482 patients evaluated in an ambulatory setting (Cortigiani et al). 2001;141:621-9

Prospective Army Coronary Calcium Project

Do conventional risk factors predict subclinical coronary artery disease? Results from the Prospective Army Coronary Calcium Project (Taylor et al). 2001;141:463-8

Prospective P²C² HIV Multicenter Study

Dilation of the aortic root in children infected with human immunodeficiency virus type 1: The Prospective P²C² HIV Multicenter Study (Lai et al). 2001;141:661-70

Pulmonary circulation

Contrast echocardiography for detection of pulmonary arteriovenous malformations (Nanthakumar et al). 2001;141:243-6

Detection of changes in diastolic function by pulmonary venous flow analysis in women athletes (Guazzi et al). 2001;141:139-47

Q

QRS complex; see Electrocardiography

QT dispersion; see Electrocardiography

Quality of Life in Angina Research Trial (QUART)

Testing the effectiveness of converting patients to long-acting antianginal medications: The Quality of Life in Angina Research Trial (QUART) (Spertus et al). 2001;141:550-8

R

Randomized controlled trials

Randomized clinical trials and recent patterns in the use of statins (Wang et al). 2001;141:957-63

Reference standards

Need for standardization of noninvasive assessment of vascular endothelial function (Kuvin et al). 2001;141:327-8 (Editorial)

Remodeling, ventricular; see Ventricular remodeling

RENEWAL Study

A Randomised Trial of Endoluminal Reconstruction Comparing the NIR Stent and the Wallstent in Angioplasty of Long Segment Coronary Disease: Results of the RENEWAL Study (Nageh et al). 2001;141:957-63

Renin-angiotensin system

Lack of association among five genetic polymorphisms of the renin-angiotensin system and cardiac hypertrophy in patients with aortic stenosis (Ortlepp et al). 2001;141:671-6

Systemic and renal effects of atrial natriuretic peptide in patients with heart failure treated with angiotensin-converting enzyme inhibitor or in acute saline solution loading (Tomiyama et al). 2001;141:422-7

Reperfusion

Early peak creatine kinase activity is not always a marker of successful reperfusion with myocardial salvage in patients with reperfused anterior acute myocardial infarction (Kosuge et al). 2001;141:759-64

Prognosis of patients with a recurrent acute myocardial infarction before and in the reperfusion era—A national study (Shotan et al). 2001;141:478-84

Reproducibility of results

Reproducibility of exaggerated blood pressure response to exercise in healthy patients (Sharabi et al). 2001;141:1014-7

Revascularization; see Myocardial revascularization

Risk factors

And the beat goes on (O'Rourke). 2001;141:319-20 (Editorial)

Do conventional risk factors predict subclinical coronary artery disease? Results from the Prospective Army Coronary Calcium Project (Taylor et al). 2001;141:463-8

Established and emerging cardiovascular risk factors (Wood). 2001;141:S49-57

INTER-HEART: A global study of risk factors for acute myocardial infarction (Öunpuu et al). 2001;141:711-21 (Prog. cardiol.)

Joint effects of C-reactive protein and other risk factors on acute coronary events (Kervinen et al). 2001;141:580-5

ROSETTA Registry

Use of routine functional testing after percutaneous transluminal coronary angioplasty: Results from the ROSETTA Registry (Eisenberg et al). 2001;141:837-46

S

Safety

Safe and effective for children? (Schreiner and Greeley). 2001;141:3-5 (Editorial)

Safety, feasibility, and prognostic implications of pharmacologic stress echocardiography in 1482 patients evaluated in an ambulatory setting (Cortigiani et al). 2001;141:621-9

Safety management

- The Data and Safety Monitoring Committee: Some final thoughts (DeMets and Yusuf). 2001;141:548-9 (Meetings)
- Data and safety monitoring committees: Philosophy and practice—Introduction (Califf and Lee). 2001;141:154-5 (Meetings)
- Making changes in clinical trials (Weaver and Greenberg). 2001;141:295-300 (Meetings)
- Procedures of Data and Safety Monitoring Committees (Pocock and Furberg). 2001;141:289-94 (Meetings)
- Regulatory issues for Data and Safety Monitoring Committees (Fisher and Klibaner). 2001;141:536-41 (Meetings)
- Should all trials have a Data Safety and Monitoring Committee? (Cairns et al). 2001;141:156-63 (Meetings)
- Statistical approaches and policies for the operations of Data and Safety Monitoring Committees (Califf and Ellenberg). 2001;141:301-5 (Meetings)
- Terms of reference for Data and Safety Monitoring Committees (Packer et al). 2001;141:542-7 (Meetings)

Shock, cardiogenic

- Percutaneous coronary intervention for cardiogenic shock in the SHOCK Trial Registry (Webb et al). 2001;141:964-70
- Recent magnitude of and temporal trends (1994-1997) in the incidence and hospital death rates of cardiogenic shock complicating acute myocardial infarction: The second National Registry of Myocardial Infarction (Goldberg et al). 2001;141:65-72
- The use of intra-aortic balloon counterpulsation in patients with cardiogenic shock complicating acute myocardial infarction: Data from the National Registry of Myocardial Infarction 2 (Barron et al). 2001;141:933-9

Smoking

- Effect of smoking status and abciximab use on outcome after percutaneous coronary revascularization: Pooled analysis from EPIC, EPILOG, and EPISTENT (Cho et al). 2001;141:599-602

Smooth muscle, vascular; see Muscle, smooth, vascular

Socioeconomic factors

- Heart failure disease management in an indigent population (O'Connell et al). 2001;141:254-8
- Potential impact of socioeconomic differences on clinical outcomes in international clinical trials (Shibata et al). 2001;141:1019-24 (Meetings)

Sodium chloride

- Systemic and renal effects of atrial natriuretic peptide in patients with heart failure treated with angiotensin-converting enzyme inhibitor or in acute saline solution loading (Tomiya et al). 2001;141:422-7

SPECT; see Tomography, emission-computed, single-photon

ST segment; see Electrocardiography

Standardization; see Reference standards

Statins; see Anticholesteremic agents

Statistics

- Statistical approaches and policies for the operations of Data and Safety Monitoring Committees (Califf and Ellenberg). 2001;141:301-5 (Meetings)

Stents

- Coronary stenting and platelet glycoprotein IIb/IIIa receptor blockade in acute myocardial infarction (Santoro and Bolognese). 2001;141:S26-35
- Effects of cilostazol on late lumen loss and repeat revascularization after Palmaz-Schatz coronary stent implantation (Kozuma et al). 2001;141:124-30
- Infarct artery reocclusion after primary angioplasty, stent placement, and thrombolytic therapy for acute myocardial infarction (Wilson et al). 2001;141:704-10 (Prog. cardiol.)

Long-term prognostic value of ²⁰¹Tl single-photon emission computed tomographic myocardial perfusion imaging after coronary stenting (Cottin et al). 2001;141:999-1006

Prognostic value of absolute versus relative measures of the procedural result after successful coronary stenting: Importance of vessel size in predicting long-term freedom from target vessel revascularization (Ziada et al). 2001;141:823-31

A Randomised Trial of Endoluminal Reconstruction Comparing the NIR stEnt and the Wallstent in Angioplasty of Long Segment Coronary Disease: Results of the RENEWAL Study (Nageh et al). 2001;141:971-6

Six-month angiographic follow-up after intravascular ultrasound-guided stenting of infarct-related artery: Comparison with non-infarct-related artery (Hong et al). 2001;141:832-6

Treatment of focal in-stent restenosis with balloon angioplasty alone versus stenting: Short- and long-term results (Mehran et al). 2001;141:610-14

Stress test; see Exercise test

Stroke volume

Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: Results of a meta-analysis (Packer et al). 2001;141:899-907

Strong Heart Study

- A population-based assessment of left ventricular systolic dysfunction in middle-aged and older adults: The Strong Heart Study (Devereux et al). 2001;141:439-46
- Relationship of impaired glucose tolerance to left ventricular structure and function: The Strong Heart Study (Ilersic et al). 2001;141:992-8

Syncope

- Formal analysis of the optimal duration of tilt testing for the diagnosis of neurally mediated syncope (Stein et al). 2001;141:282-8
- Predictive value of presyncope in patients monitored for assessment of syncope (Krahn et al). 2001;141:817-21

T

Tachycardia, supraventricular

Amiodarone is safe and highly effective therapy for supraventricular tachycardia in infants (Etheridge et al). 2001;141:105-10

Tedelparin

Dalteparin in combination with abciximab during percutaneous coronary intervention (Kereiakes et al). 2001;141:348-52

Thallium radioisotopes

Long-term prognostic value of ²⁰¹Tl single-photon emission computed tomographic myocardial perfusion imaging after coronary stenting (Cottin et al). 2001;141:999-1006

Thrombectomy

Rheolytic thrombectomy during percutaneous revascularization for acute myocardial infarction: Experience with the AngioJet catheter (Silva et al). 2001;141:353-9

Thrombin inhibitors; see Fibrinolytic agents

Thromboembolism

- Antithrombotic therapy after prosthetic cardiac valve implantation: Improving postoperative, long-term patient management—Introduction (Berkowitz). 2001;141:847-8 (Meetings)
- Better delivery of standard antithrombotic care (Bussey). 2001;141:xx25 (Meetings)
- Novel intravenous antithrombins (Levy). 2001;141:1043-7 (Meetings)
- Pathobiologic features and prevention of thrombotic complications associated with prosthetic heart valves: Funda-

mental principles and the contribution of platelets and thrombin (Becker et al). 2001;141:xx24 (Meetings)

Thrombolytic therapy

- Abciximab and early adjunctive percutaneous coronary intervention are associated with improved ST-segment resolution after thrombolysis: Observations from the TIMI 14 Trial (de Lemos et al). 2001;141:592-8
- Corrected TIMI frame counts correlate with stenosis severity and infarct zone wall motion after thrombolytic therapy (Amos et al). 2001;141:586-91
- Determination of a weight-adjusted dose of TNK-tissue plasminogen activator (Wang-Clow et al). 2001;141:33-40
- Infarct artery reocclusion after primary angioplasty, stent placement, and thrombolytic therapy for acute myocardial infarction (Wilson et al). 2001;141:704-10 (Prog. cardiol.)
- Interventional procedures in acute myocardial infarction (DeGeare et al). 2001;141:15-24 (Curriculum cardiol.)
- Outcome of acute ST-segment elevation myocardial infarction in patients with prior coronary artery bypass surgery receiving thrombolytic therapy (Labinaz et al). 2001;141:469-77
- Recurrent ischemia after thrombolysis for acute myocardial infarction (Pilotte et al). 2001;141:559-65

Tilt-table test

- Formal analysis of the optimal duration of tilt testing for the diagnosis of neurally mediated syncope (Stein et al). 2001;141:282-8

TIMI 14 Trial

- Abciximab and early adjunctive percutaneous coronary intervention are associated with improved ST-segment resolution after thrombolysis: Observations from the TIMI 14 Trial (de Lemos et al). 2001;141:592-8

Tissue-inhibitor of metalloproteinase-1

- Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome (Inokubo et al). 2001;141:211-17

Tissue plasminogen activator

- Determination of a weight-adjusted dose of TNK-tissue plasminogen activator (Wang-Clow et al). 2001;141:33-40

Tomography, emission-computed, single-photon

- Evaluation of β -blocker therapy in patients with dilated cardiomyopathy—Clinical meaning of iodine 123-metaiodobenzylguanidine myocardial single-photon emission computed tomography (Yamazaki et al). 2001;141:645-52
- Gated single-photon emission computed tomographic myocardial imaging: A new tool in clinical cardiology (Bavelaar-Croon et al). 2001;141:383-90
- Long-term prognostic value of ^{201}Tl single-photon emission computed tomographic myocardial perfusion imaging after coronary stenting (Cottin et al). 2001;141:999-1006

Tomography, x-ray computed

- Aggressive versus moderate lipid-lowering therapy in postmenopausal women with hypercholesterolemia: Rationale and design of the Beyond Endorsed Lipid Lowering with EBT Scanning (BELLES) trial (Raggi et al). 2001;141:722-6 (Trial design)
- Use of electron beam tomography data to develop models for prediction of hard coronary events (Raggi et al). 2001;141:375-82

Treatment outcome; see Outcome assessment (health care)

Troponin I; see Biological markers

U

Ultrasonography, interventional

- Characterization of atherosclerotic plaque by magnetic resonance imaging (Frank). 2001;141:S45-8

- Six-month angiographic follow-up after intravascular ultrasound-guided stenting of infarct-related artery: Comparison with non-infarct-related artery (Hong et al). 2001;141:832-6

United States Food and Drug Administration

- Designing trials for testing prosthetic cardiac valves: A Food and Drug Administration perspective (Sapirstein). 2001;141:861-3 (Meetings)

Uric acid

- Uric acid in cachectic and noncachectic patients with chronic heart failure: Relationship to leg vascular resistance (Doehner et al). 2001;141:792-9

V

Vascular resistance

- Uric acid in cachectic and noncachectic patients with chronic heart failure: Relationship to leg vascular resistance (Doehner et al). 2001;141:792-9

Vasodilation

- Evidence suggesting coronary vasodilation as the principal mechanism in the warm-up phenomenon (Ylitalo et al). 2001;141:e10

Vasodilator agents

- Testing the effectiveness of converting patients to long-acting antianginal medications: The Quality of Life in Angina Research Trial (QUART) (Spertus et al). 2001;141:550-8

Ventricular dysfunction, left

- Congenital left ventricular aneurysm: Clinical, imaging, pathologic, and surgical findings in seven new cases (Papagiannis et al). 2001;141:491-9
- Does the presence of hibernating myocardium in patients with impaired left ventricular contraction affect QT dispersion? (Al Mohammad et al). 2001;141:944-8
- Elevated interleukin-6 levels in patients with asymptomatic left ventricular systolic dysfunction (Raymond et al). 2001;141:435-8
- Improved survival of patients with acute myocardial infarction with significant left ventricular dysfunction undergoing invasive coronary procedures (Rott et al). 2001;141:267-76
- Parasympathetic dysautonomia precedes left ventricular systolic dysfunction in Chagas disease (Ribeiro et al). 2001;141:260-5
- A population-based assessment of left ventricular systolic dysfunction in middle-aged and older adults: The Strong Heart Study (Devereux et al). 2001;141:439-46
- Prediction of the extent and severity of left ventricular dysfunction in anterior acute myocardial infarction by the admission electrocardiogram (Birnbaum et al). 2001;141:915-24
- Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction (Maisel et al). 2001;141:367-74

Ventricular function, left

- An angiotensin-converting enzyme inhibitor improves left ventricular systolic and diastolic function in transfusion-dependent patients with β -thalassemia major (Karvounis et al). 2001;141:e7
- Effect of metoprolol on rest and exercise left ventricular systolic and diastolic function in idiopathic dilated cardiomyopathy (Clements and Miller). 2001;141:e5
- Effect of the stenosis location and severity on left ventricular function after single-vessel anterior wall myocardial infarction (Kachi et al). 2001;141:55-64
- Gated single-photon emission computed tomographic myocardial imaging: A new tool in clinical cardiology (Bavelaar-Croon et al). 2001;141:383-90

Influence of treatment delay on long-term left ventricular function in patients with acute myocardial infarction successfully treated with primary angioplasty (Sheiban et al). 2001;141:603-9

Left ventricular function and hemodynamic features of inappropriate left ventricular hypertrophy in patients with systemic hypertension: The LIFE Study (Palmieri et al). 2001;141:784-91

Relationship of impaired glucose tolerance to left ventricular structure and function: The Strong Heart Study (Iltercil et al). 2001;141:992-8

Ventricular function, right

Right ventricular diastolic function in β -thalassemia major: Echocardiographic and clinical correlates (Hahalis et al). 2001;141:428-34

Ventricular hypertrophy, left; see Hypertrophy, left ventricular

Ventricular outflow obstruction

Evaluation and follow-up of patients with left ventricular apical to aortic conduits with 2D and 3D magnetic resonance imaging and Doppler echocardiography: A new look at an old operation (Fogel et al). 2001;141:630-6

Ventricular remodeling

Heterogeneity of left ventricular remodeling after acute myocardial infarction: Results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-3 Echo Substudy (Giannuzzi et al). 2001;141:131-8

Regional wall stress predicts ventricular remodeling after anteroapical myocardial infarction in the Healing and Early Afterload Reducing Trial (HEART): An echocardiography-based structural analysis (Aikawa et al). 2001;141:234-42

W

Warm-up phenomenon

Evidence suggesting coronary vasodilation as the principal mechanism in the warm-up phenomenon (Ylitalo et al). 2001;141:e10

Women

Aggressive versus moderate lipid-lowering therapy in postmenopausal women with hypercholesterolemia: Rationale and design of the Beyond Endorsed Lipid Lowering with EBT Scanning (BELLES) trial (Raggi et al). 2001;141:722-6 (Trial design)

Coronary microvascular dysfunction is highly prevalent in women with chest pain in the absence of coronary artery disease: Results from the NHLBI WISE study (Reis et al). 2001;141:735-41

Detection of changes in diastolic function by pulmonary venous flow analysis in women athletes (Guazzi et al). 2001;141:139-47

Efficacy of atorvastatin in achieving National Cholesterol Education Program low-density lipoprotein targets in women with severe dyslipidemia and cardiovascular disease or risk factors for cardiovascular disease: The Women's Atorvastatin Trial on Cholesterol (WATCH) (McPherson et al). 2001;141:949-56

Unstable angina in the Myocardial Infarction Triage and Intervention Registry (MITI): Short- and long-term outcomes in men and women (Kim et al). 2001;141:73-7

